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1. Introduction  
1.1. Background and conceptualization 
Chronic obstructive pulmonary disease (COPD) is a severe respiratory disorder that 
poses a tremendous burden on healthcare and economic resources. The prevalence of 
COPD has been steadily rising globally (1) and COPD-associated mortality is predicted 
to be the third-leading cause of death by 2020 (2). While smoking is one of the major 
risk factors for developing COPD, other triggers include age, genetic predisposition, and 
a history of bronchial asthma and recurrent respiratory infections (3). Age and COPD 
prevalence appear to have a positive correlation and approximately 9.0-10.0% of the 
>40-years population present with COPD (4). 
The main goal in COPD management is to maintain stable lung function and prevent 
acute exacerbations. The pharmacotherapy of COPD includes bronchodilators such as 
β2-adrenergic agonists (BAs) and muscarinic antagonists (MAs), and inhaled 
corticosteroids (5). The preferred route of administration of these agents is via the 
inhalation due to its advantages – smaller dose, rapid onset of action, and lower 
incidence of side-effects (6) numerous inhaler devices are available to COPD patients 
for use in maintenance therapy. However, similar to other chronic conditions, successful 
disease management relies intrinsically on treatment adherence, and poor adherence to 
inhaler therapies has been shown to be associated with an increase in mortality rates, 
hospitalization, and disease burden in COPD patients (7; 8). 
Chronic health-related conditions such as COPD have an enormous impact on the 
patient’s quality-of-life (QoL) and result in increased utilization of health services. 
Patients who are unable to self-manage their chronic condition also score low on health 
literacy, a modifiable risk factor that can be rectified through effective patient 
communication (9). Patient education programs improve patients’ health awareness and 
knowledge, symptom management, self-care practices and overall health status (10; 11; 
12) thereby reducing the propensity for negative outcomes and associated treatment 
costs (13; 14). Similar programs designed for patients with COPD have been 
implemented, especially around exacerbations (15; 16; 17), in community pharmacy 







studies looking at the impact of patient education programs on QoL or adherence or both 
(22; 23; 24; 25; 26) in patients with COPD.  
Despite an enormous wealth of information on the effectiveness of patient education in 
the management of COPD in other parts of the world, there is a noticeable paucity of 
data from Hungary. Hence, the main goal of our study was to address these shortcomings 
and our primary objective was to assess the effect of patient education on medication 
adherence and QoL in COPD patients. We also sought to analyze whether demographic 
and subgroup parameters influenced adherence and QoL. The available resources and 
facilities enabled us to pick this challenging, but so far less studied and promising 
scientific area.  
Compliance expresses the extent to which a patient is loyal to the duration of the 
recommended medication, to the dose of the recommended drug(s), and to 
administration frequency (27). It is an important feature of the therapy, though it does 
not reflect any collaboration from the patient’s side. According to the WHO, adherence 
is “the behavior of an individual in accordance with recommendations agreed with a 
health care professional in the field of medication, diet and lifestyle change” (28), while 
another source refers to adherence when an individual is taking medication and 
collaborates with change according to health care recommendations (29). While 
compliance is primarily a matter of following medical instructions, adherence is a 
feature of patient collaboration. The term “adherence” will be used throughout this 
dissertation, which also demonstrates my dedicated to patient-centered therapy. I 
believe that the therapeutic experience can only be achieved if the patient is actively 
involved in it. 
Patient education will act as an umbrella term to refer to any action that the patient 
implements to increase their acceptance, improve their attitudes, as well as the same on 
the educator’s side. I will apply “quality of life” in an extended meaning referring to the 
environment, income and household of the COPD patient, considering that this body of 
research was implemented in the healthcare context. Thus, the mental, physical, self-
role (work, parent, and career) dimensions and social function (relationship, fitness, 
health perception, satisfaction and well-being) are also included – as opposed to the 







1.2. COPD: a current snapshot 
This chapter has the aim to provide an insight into COPD care, its impact on the society 
and the patient. It highlights the major pathophysiology aspects, comorbidities and 
extensively discusses current therapeutic options. This background is important to 
understand the world of the patient with stable COPD, who will be in focus in the further 
chapters.  
1.2.1. Epidemiology and social burden 
The prevalence of COPD varies from country to country but represents a significant 
health and economic burden (1). The most important predisposing factor for the 
development of the disease is smoking (31), besides inhalation of environmental 
hazards, dust, contaminated air, occupational hazards, and infections (32).  
According to the Rotterdam Study (33), the overall prevalence in the population should 
be around 5%. Prevalence changed significantly between 1990 and 2020, moving from 
the sixth to the third place as a leading death cause (2). This is supported by that the 
proportion of the elderly increases in aging societies, so the condition is expected to soar 
in absolute, as well as in relative numbers (1). By the age of 40, the prevalence of COPD 
rises to 9-10% (4).  
The intrinsic deterioration of quality of life due to COPD, which frequently goes in pair 
with low medication rate, can be measured by quality of life questionnaires (34). The 
more symptomatic is the patient, the lower is their quality of life, and the greater is the 
social burden (1). This burden can be alleviated by effective measures to foster early 
diagnosis and to keep the patient engaged (35). 
Between 1987 and 2009, a summary of 11 studies found that COPD patients were in the 
range of 56-69% vs. 65-77% non-COPD patients to be able to perform their work (36). 
Besides, directly incurred health costs, we should take into consideration the financial 
loss late diagnosis, lost working hours and loss of productivity can generate. 








1.2.2. Patient flow and infrastructure of COPD care and implications to Hungary 
Patients with COPD are often diagnosed late (38) , so patients are referred to a physician 
only when symptoms get more prevalent (an important note to patient referral: outside 
Hungary, COPD patients are usually treated by GPs – the description below primarily 
considers the context of this study, so I limit the scope to Hungary). The first encounter 
for the patient in the healthcare sytems are the GP and nurse. Patients mainly report 
coughing, sputum and breathlessness; however, GPs do not always feel competent to 
treat COPD patients (39; 40). Pulmonologists report that even the condition may remain 
undiagnosed even after multiple exacerbations, since patients are only taking multiple 
antibiotic and expectorant treatment; thus, they support that patient care should be 
reinforced in the GP office (41). 
The GP is a gatekeeper in the healthcare system: they can decide to treat a condition in 
their office; or to direct the patient to specialist care (or primary care, as referred to more 
often by international articles) (42). In order to facilitate the healthcare access process, 
patients can participate in COPD screening on a voluntary basis, and the GP can also 
refer their patients here, and an early diagnosis of the disease could be made with the 
participation of a pulmonologist (40). This is often not the case because of the lack of 
awareness of the disease or the patient’s unwillingness to cooperate (43). In general, 
patients do not have a direct access to the pulmonologist, and they should be referred by 
the GP (44). 
With the GP referral, the first pulmonologist consultation appointment is given to the 
patient within 1-6 weeks of time, depending on the actual workload of the pulmonology 
outpatient center. Here, the usual diagnostic procedures are made: lung function and the 
bronchodilator tests (39; 45), which is supplemented by health status assessment tools, 
supported by the GOLD guidelines (46). 
Cormorbidities, if present, are usually treated by another specialist (47; 48) may that be 
a cardiology or oncology. Following the resolution of the comorbidity, the patient 
returned to the lung care provider for specialist advice and will be treated for COPD 







After medication is prescribed, the pulmonologist, or the nurse provides some training, 
which normally includes inhaler use (49), especially if the patient has questions, finds it 
difficult to use, is uncertain about the therapy (50). The therapy can only be successful 
on the long-term, if the device is chosen according to the patient’s needs and they are 
able to use it (51). 
The lung specialist will usually return the patient to a two-week (in the case of therapy 
initiation) up to twelve-month check-up (in case of well-established maintenance 
therapy). The pulmonologist can issue a license to the GP, so that they can prescribe 
pulmonology medication with high reimbursement rate; thus, the pulmonologist-patient 
relationship becomes much less frequent than that of the GP and the patient (52). 
Studying the process reveals that patient information can be obtained from the 
pulmonary therapist, the respiratory assistant, and the pharmacy (53). The intervention 
points of the PhD study were designed accordingly: quality of life and the adherence of 
the patients were monitored in the pulmonary outpatient center and the pharmacy. 
Exploratory and in-depth interviews were conducted with participants and 
pulmonologists, to gather information at the most major intervention points of care. 
Figure 1 summarizes the patient flow of the study. 
 
Figure 1: Intervention points in the patient flow in Hungary 
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1.2.3. Pathophysiology & biochemistry. Phenotypes 
The clinical appearance of COPD is chronic inflammation of the respiratory tract, of the 
lung parenchyma, and the vasculature (54). Irritant agents, often deriving from smoking, 
elicit an inflammatory immune response, which becomes permanent and causes tissue 
destruction. The result of the TGFβ pathway (55) is fibrotic lesion formation, first 
presents as small airway obstruction, and gradually expand to the bronchi (this makes it 
understandable that COPD can show a certain reversibility if diagnosed early. The 
macrophage pathway (56) creates the two phenotypes of COPD (Table 1). In patients 
with emphysema, T-cell inflammation or protease activity predominate, and the walls 
of the alveoli become ruptured, consequently the effective respiratory surface is 
reduced, and the surrounding vasculature is damaged. Reduced active respiratory 
surface develops adaptive hyperventilation; however, gas exchange is damaged. The 
result of the neutrophil/monocyte and protease pathway is the mucus hypersecretion, 
which yields bronchitis and colonization of bacteria. If the airways of the patient are 
blocked by mucus, clinical symptoms will include coughing, spitting and hawking, but 
no tissue destruction occurs. Finally, this process leads to the appearance of 
hypoventilation, which results a plummeting rate of gas exchange (56). Figure 2 
provides an overview of the inflammatory pathways. 
 
Figure 2: Inflammatory processes in COPD1 
 







The most common symptoms are dyspnea, cough and/or sputum production, which 
worsen in the morning and are often accompanied by the suffocating feeling due to 
inability to get rid of the mucus (GOLD 2019). Irritating agents increase the number and 
size of mucinous cells, which produce more and more mucus; furthermore, the hair 
follicles are unable to self-cleanse, causing stagnant secretions to cause coughing and 
purging. Chest pain and shortness of breath may occur; usually these are the symptoms 
that bring the patient to a lung care provider. Exacerbations caused by colonized bacteria 
in mucus are common. Hyperinflation of the chest makes it hard for the patient to exhale; 
this is a process that develops gradually, and patients often get used to it, as well as to 
the decreased ability to perform physical activities and to become breathless rapidly 
(57). 
Table 1: COPD phenotypes: the „pink puffer” and the „blue bloater”2 






later, after 60 years of age  
(effort dyspnea) 
manifestation earlier, after 40 years of age 
no coughing or cracking symptoms cough, purulent, copious secretion 
breathing by pursed lips & breathing 
muscles 
breathing extensive use of accessory breathing 
muscles 
whistling, barely audible heartbeat  
(„barrel chest”) 
characteristics breathing noises and beeps 
„pink puffer” – hyperventilated, pink 
skin, no cyanosis 
 „blue bloater” – cardiac complaints, 
cyanosis, cor pulmonale, oedema 
 
2 Images were taken from: https://www.netterimages.com/images/vpv/000/000/013/13539-










In chronic inflammation, the lungs are unable to get rid of the irritant, resulting in 
persistent mild inflammation, which impairs blood supply to the surrounding tissues and 
increases the risk of exacerbations (58). In the long run, this leads to tissue remodeling, 
and this is the moment where the process becomes irreversible. Secretion increases, 
which aggravates the symptoms and increases airway obstruction; additional cytokines, 
growth factors and proteases are produced (59). However, squamous cell metaplasia and 
goblet cell hyperplasia can be slowed by long-term (>3.5 years) nicotine abstinence 
(60), ie, if the patient stops smoking, inflammation would not disappear, mucus 
production and tissue remodeling would decrease. 
1.2.4. Comorbidities  
The majority of COPD patients suffer from multimorbid conditions, ie they have other 
diseases than COPD (55; 61). According to current guidelines, comorbidities should be 
treated as if they were present alone (62).  
However, due to drug interactions, it is important to understand the background of these 
diseases and to select the drug for the patient that does not adversely affect the comorbid 
status, or make such a therapeutic choice for COPD, which has benefit on the other 
condition (63). The most common comorbidities are osteoporosis, anxiety / panic attack, 
heart problems, heart attack, diabetes (64), and 97.7% had at least one comorbidity and 
53.5% had four (65). The number of comorbidities increases with age (61; 48). 
Recently, the asthma-COPD overlap syndrome (ACOS) has gained increasing interest 
(66). It is estimated that 15-20% of COPD patients are affected by the overlap syndrome 
(67), which means that their condition have features resembling both COPD and asthma. 
These patients are generally younger, they are mostly in GOLD groups A or B, and no 
difference was found in exacerbation rate vs. patients with only one diagnosis (68). The 
bronchodilator test and exhaled NO levels can be used to discover the asthmatic 
component to be present, because these patients show incomplete reversibility with 
variable symptoms (67). The risk of exacerbations and the cost of treatment is higher 
than the one for only one condition being present, and mortality has been shown to be 
higher (69). Since the asthmatic eosinophilic inflammation responds well to steroids, 







not excluded from our research, so it should be considered as the comorbidity of the 
highest prevalence (with a ca. 20% rate). 
1.2.5. Treatment 
1.2.5.1. Non-pharmacological options 
Smoking is a major cause and a massively aggravating factor in COPD, so the first step 
to any result should be smoking cessation (71). Continuing smoking not only enhances 
morning symptoms and mucus production, but also accelerates functional changes in 
the bronchi and contributes to the development of irreversible obstruction (60). In case 
of early diagnosis of COPD, smoking cessation can have some visible effects; 
otherwise, it is desired in any phase of the condition (71). The patient should be directed 
to a group or personal withdrawal program according to their preferences (72). 
Referral to rehabilitation normally takes place after hospitalization or a major contact 
with the pulmonologist. Sessions include individualized care, and the methodology is 
as follows: the patient meets with a physiotherapist 2-3 times a week for 6 weeks, then 
again with the doctor after 6 weeks. This framework enables them to fill in quality of 
life, physical and depression tests to assess the effectiveness of rehabilitation (73).  
Rehabilitation is also an option in Hungary, though patients are less willing to participate 
– this might be due to dropout from work and confrontation with working hours. 
Rehabilitation effectiveness is documented in literature and recommended from GOLD 
stage B (74). The physical activity component should be highlighted, because it 
improves the patient’s life expectancy and quality of life (73); certainly, in such a form 
that is implemented according to the age and health status of the patient (75).  
Pneumococcal vaccination is recommended (57), taking into consideration that the 
weakened immune system of COPD patients and their limited lung function make them 








1.2.5.2. Pharmacological options 
1.2.5.2.1. Diagnosis and GOLD classification 
International guidelines of GOLD 2019 (57) describe diagnostic and classification tool, 
which is based on three pillars. These should be evaluated for each patient individually, 
and should be the primary factor to drive therapeutic decisions. Figure 3 summarizes 
the factors driving therapeutic decisions. 
 
Figure 3: Pillars of COPD diagnosis and status assessment 
The diagnosis of COPD can be established, if the patient is unable to exhale at least 70% 
of their vital capacity in one second (or 70% ≥FEV1/FVC) (45). This step is called the 
spirometrically confirmed diagnosis (57). 
In order to select the right treatment, patients should be classified in GOLD A, B, C, D 
groups, based on their symptoms and exacerbation risk – this implies that the assessment 
of FEV1 is no longer the golden standard of COPD care (76), because what is important 
is how the patient feels about their condition. GOLD I-IV groups are still used to assess 
airflow limitation, but risk and symptoms are assessed in a square-shape system (the 
more symptomatic is the patient, the more to the right, and the higher the exacerbation 
risk, more upwards). Figure 4 is a modified image from GOLD 2019, and clearly 
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Figure 4: Diagnosis of COPD according to GOLD 2019 
Symptomatology and exacerbation risk are equally important in assessing the status of 
COPD patients. Since exacerbators are excluded from the study, I will only focus on 
stable state in any part of the dissertation.  
According to GOLD 2019, the overall aim of to reduce symptoms (relieve symptoms, 
improve exercise tolerance, and improve health status) and to reduce risk (prevent 
disease progression, prevent and treat exacerbations and reduce mortality). 
1.2.5.2.2. Management of stable COPD 
Since the study focusses on patients with stable COPD, and excludes patients with an 
exacerbation history in the last 6 months, this theoretical overview will be limited to the 
treatment of stable COPD. GOLD recommendations provide the official opinion of 
pulmonologists, though local regulations might slightly differ. Currently, in Hungary, 
the main stakeholder in COPD medication selection is the pulmonologist. The majority 
of the medication have high reimbursement, so prescribers should also obey the rules of 








Table 2: Treatment options in COPD (unavailable solutions for Hungary are marked in grey) 
Patient 
group 
First line Alternative Optional 
A SAMA or SABA LAMA or LABA or 
SAMA+SABA 
theophylline 
B LAMA or LABA LAMA+LABA SABA and/or SAMA; 
theophylline 
C ICS+LABA or LAMA LAMA+LABA or 
LAMA+PDE4-inhibitor or 
LABA+PDE4-inhibitor 
SABA and/or SAMA; 
theophylline 
D ICS+LABA and/or 
LAMA  
ICS+LABA and LAMA 





cysteine; SABA and/or 
SAMA; theophylline 
Table 2 provides an insight into the therapeutic options. Generally, long-acting 
bronchodilators are preferred over short-acting bronchodilators (77; 78), and combined 
inhalers yield greater results than monotherapy (79). Therapies are normally built up in 
a consecutive augmentation fashion: starting by one component of a fixed-dose 
combination, and adding the second (third) later (80).  
In very mild forms of COPD, SAMA and SABA can be used. These are normally the 
part of an adjunctive therapy besides the long-acting agents, since COPD is barely 
diagnosed at this stage. From GOLD B onwards, LAMA is the most frequent choice in 
Hungary, although LABA can be used in monotherapy, too. LAMA seems to have 
therapeutic benefits over LABA in terms of rehabilitation and in reducing exacerbation 
risk (57). In case of contraindication, consultation with an ophthalmologist, urologist, 
and cardiologist is needed (81), and the other agent should be preferred. In case of 
worsening of the disease, this therapy is supplemented with LABA or LAMA. Cardiac 
effects of LABAs have caused certain difficulties in adding it to the therapy (82). It is 
important to note; however, that hypoxia that develops as a consequence of COPD, 
impairs blood oxygenation (42), which, by increasing heart rate, produces tachycardia, 
which can lead to unwanted fibrillation (which also increases the risk of stroke). Thus, 
the delivery of LABA is Janus-faced: it is worth bearing in mind cardiac comorbidities, 
but it is not necessary to vacillate with advancement, since it is in the patient's interest 







of both agents seems to be a reasonable option to counteract the downward spiral of 
COPD. As of the international guidelines, the combination therapy can be initiated from 
the beginning (84). 
ICS+LABA is a base therapy for COPD from GOLD C, and the reasons behind it go 
completely aligned with the pathophysiology: local steroid treatment is an effective way 
to alleviate inflammatory processes. Recently, their previous supremacy in exacerbation 
risk reduction has been questioned, since it has been demonstrated that they have no 
superior effect in this regards compared to LAMA treatment (57). Consequently, a 
therapeutic need for triple combinations arises: this is a recently available option. This 
contains all standard pharmaceutical agents (LAMA+LABA+ICS).  
As an adjunctive therapy, it is possible to administer expectorant agents (carbocysteine 
and N-acetylcysteine), which may play a role in sputum removal, but no long-term 
effects have been shown on patient health status. At these phase, roborants and 
nutritional solutions might be needed to counteract cachexia. Due to narrow therapeutic 
window of theophylline derivatives, they are only recommended in adjunctive therapy, 
especially if the patient is unable to cooperate with inhalative therapy. Oxygen therapy 
is deployed at later phases of COPD – this is the ultima ratio to ensure O2 saturation 
(57).  
SAMA and SABA use as “relievers” is excessive. Underlying reasons can be low price, 
high availability (they can be prescribed by GPs), and fast onset of action; and these 
decrease patient adherence to long-acting medication. They indeed have a definite role 
in COPD therapy, though it should be noted that correctly built-up maintenance therapy 
requires no or minimal reliever use.   
Table 3 provides an insight into the myriad of the therapeutic options to each 








Table 3: Overview of inhalative medication indicated for COPD treatment in Hungary 
mechanism of action active agent inhaler brand name 
Muscarinergic antagonists (MAs) 
SAMA ipratropium bromide pMDI Atrovent N 
LAMA tiotropium bromide DPI, SMI Spiriva Handihaler & Respimat 
 glycopyrronium 
bromide 
DPI Seebri Breezhaler 
 aclidinium bromide DPI Bretaris Genuair 
 umeclidinium bromide DPI Incruse Ellipta 









SMI Spiolto Respimat 
 glycopyrronium 
bromide+indacaterol 
DPI Ultibro Breezhaler 
 aclidinium 
bromide+formoterol 
DPI Brimica Genuair 
ICS+LABA+LAMA umeclidinium+fluticas
one furoate +vilanterol 
DPI Trilegy Ellipta 
 glycopyrronium 
bromide + formoterol + 
beclometasone 
pMDI Trimbow spray 
β2-agonists (BAs) 
SABA salbutamol pMDI Ventolin Evohaler, Buventol 
Easyhaler 
 terbutaline DPI,  
injection 
Bricanyl 




 formoterol pMDI/DPI Atimos spray, Foradil Aerolizer, 
Reviform Axahaler 
 indacaterol DPI Onbrez Breezhaler 
 olodaterol SMI Striverdi Respimat 
 salmeterol pMDI/DPI Serevent Evohaler 
Inhalative corticosteroids (ICS) 
ICS+LABA beclometason+formote
rol          
pMDI Foster spray 








 fluticasone propionate 
+salmeterol 
DPI Seretide/Thoreus Diskus, Dimenio 
Elpenhaler, Fullhalle spray, 
Airflusol Forspiro 
 fluticasone furoate 
+vilanterol 
DPI Relvar Ellipta 
1.2.5.2.3. Specific considerations of inhalation therapy 
Inhalers and inhalative treatment are preferred in current COPD therapy (85), whose 
selection requires special attention. It provides an opportunity to tailor-make the therapy 
to the patient’s needs (51). The patient's symptoms, intelligence, expected degree of 
adherence should be taken into account in the selection process (77).  
Pulmonologist interviews reveal that the use of pMDI / DPIs is considered simpler and 
may be chosen due to lack of time. Concerning the use of the SMI tool (Respimat), there 
is a consensus that the therapeutic benefits outweigh the DPIs, but there is not always 
time to teach this tool, but it is considered to be the most advanced. One-time daily 
administration seems to go in line with higher adherence rate (86), though there are 
patients who feel safer to sniff for the second time in the evening. From the therapeutic 
effect point if view, twice daily administration can be beneficial for less adherent people, 
since by forgetting one shot, they still reach 50% of their daily recommended dose.  
Muscarinic antagonists act on acetylcholine receptors, and the specificity of the newer 
agents is expressed at the M3 receptor (leading to a lower rate of adverse effects). 
Cholinergic tone produces ab ovo bronchoconstriction and mucosal secretion, so its 
antagonists are physiologically bronchodilator (which implies that they elicit 
bronchodilation under physiological conditions, too). M3 receptors are located in the 
bronchi; thus, the introduction of MAs do not necessarily needs to reach the deeper 
airways. This is opposite for the BAs, since β2 receptors lie in the small airways, which 
do require that the active agent contains such particles that are able to reach high 
deposition there. Corticosteroids act on almost all components of inflammation and 
reduce airway hyperreactivity, although they have no direct bronchodilator role. They 
are believed to inhibit the decline of respiratory function (87). Table 4 is a 
pharmacological overview of mechanisms of action, and also provides and insight into 
the potential adverse effects (88), as well as contains comments of use, especially in the 











Mechanism of action Comments for use Adverse effect profile 
M3 
antagonists 
reduction of the cholinergic 
bronchial constriction 
basic therapy for 
COPD, first choice 
from GOLD B upwards 
glaucoma, urinary 
retention, dry mouth 
β2 agonists intracellular cAMP levels 
increase, smooth muscles 
relax, bronchoconstriction 
decreases 
basic therapy for 
COPD, administered 
from a separate device 
B or in FDC with 




ICS (+LABA) ICS affects all components 
of inflammation 
(intracellularly, it connects 
to a nucleus receptor, which, 
after connecting to a heat 
shock protein, induces a 
conformational change that 
sets the DNA binding 
domain free. After 
dimerization, in the 
nucleolus, it connects to the 
DNA responsive element, 
and affects transcription) 
baseline COPD therapy 
in severe cases, in 
patients with increased 
risk of exacerbation 







unknown), inhibits the 
release of inflammatory 
mediators (primarily PDE4) 
adjunctive therapy if 
the patient is unable to 
use the inhaler for 
financial or intellectual 
reasons 
cardiovascular, heart rate 
and contractility increase, 
diuretic effect 
roflumilast inhibitors of bronchial 
phosphodiesterase (PDE4) 
rarely used, though 











1.3. Appraisal of international good practice 
This chapter has the aim to provide an overview of the current research trends in the key 
areas related to my research focus: patient attitudes and perceptions, quality of life and 
adherence. Wherever possible, I considered the education aspect, and gather input to the 
development of the content. 
1.3.1. Systematic literature review 
Seeking to better understand the theoretical background of current body of research 
related to the topics of the thesis, I performed a systematic literature review. As an 
general rule, literature review was performed for each research area according to the 
PRISMA recommendations (89), see Figure 5. As an example, for the perception 
chapter, the following key words were applied: (COPD AND patient education), then 
narrowed my results ((COPD NOT asthma) AND patient education) and finally 
evaluated the most specific results (((COPD NOT asthma) AND patient education) 
AND (percept* OR literacy)). 
 







1.3.2. Perceptions, attitudes and patient knowledge 
In order to assess patient knowledge and to build relevant educational content, we should 
recognize what the patient needs and what information they already have (90). In the 
long run, only interventions that bring about changes in the patient’s daily life can be 
successful (44). The patient should be empowered to be willing to make lifestyle 
changes in their own daily rhythm that allow for better disease management. 
A further success factor of patient education that is should be tailored to existing needs, 
and should be country, population and disease specific (90). This means that before 
developing content, we should understand patients’ capabilities, current knowledge, 
perceptions and attitudes at a given location. During our studies, we assumed that the 
Hungarian population is homogenous, and the pilot studies were performed in Budapest. 
The explorative interviews targeted the above objectives.  
Initially, I wanted to observe the options of telemedicine to perform the education, 
though the current level of patient literacy turned down this ambition in the very 
beginning. It has been an interesting to see that attempts are made to educate COPD 
patients via the Internet or electronic devices, either in person or through smart devices 
(91). Further solutions include short messages, applications and other electronic means 
(92).  
The first concept for development included coping skills training, which aims at 
inducing a change in the patients’ life, starting from acceptance towards a health self-
management of the disease. Coping skills training has proven to improve emotional 
balance and quality of life (93). The strength of the study is that n=326 patients were 
followed for a total of 4.4 years, while a telemedicine study demonstrated the beneficial 
effect on mortality (91). Healthcare systems may be less available for personal 
consultation in the future (78), so patients are likely to be driven towards higher 
acceptance of telemedicine solutions (94). This opens another interesting question: this 
direct contact enables a more direct connection between educator and patient. The future 
direction of attitudes slightly is to expand the effects of personal meetings by electronic 
interaction, and a higher rate of learning and putting into practice the information needed 
to self-manage the disease (95; 96). Patients with a better perceptions and coping 







Illness Perception Questionnaire (B-IPQ) and Utrecht Proactive Coping Competence 
Scale (UPCC)), and patients with an overly emotional response to the disease impaired 
their ability to cope with it. Patients that are more educated found more delicate and 
effective coping strategies.  
In order to optimize patient outcomes, disease awareness, as well as patient perception 
should be evaluated (97; 98). Decreased acceptance or even neglecting their condition 
will yield marginal adherence. Improving these inherent characteristics of the 
therapeutic setting, and providing the patients with targeted information improves their 
quality of life (99; 100). This is not an easy path, since the patient’s ability to report 
symptoms, or to verbalize medical history can also be difficult, that underlines the 
importance that patients and caregivers should speak the same language and be on the 
same page related to understanding the disease. 
1.3.3. Patient education and self-management 
 While designing the education content, I identified similar body of research which 
describes an educational project with n = 62 patients with moderate to mild COPD (<70 
years of age), who participated 2x2 hour weekly session, with 1 week gap fashion. 
Success factors were met if the number of GP consultations and reliever use decreased 
and patient satisfaction increased (101). Education was performed through a 19-page 
booklet with information on self-assessment and disease management. Oral sessions 
included education on the respiratory obstruction, anti-obstructive medication, 
exacerbation prevention, self-assessment and self-management, and physiotherapy. 
Twenty-one patients (84%) completed the study with one year follow-up. In the treated 
group, absenteeism at work was reduced by 95% (not significant), and patient 
satisfaction was 87%; and the relationship with the GP has improved (GPs are treating 
COPD patients in this setting). Overall, the study showed no improvement in quality of 
life parameters. Limiting factors include increased participation in asthma patients, and 
the experiments were performed almost 20 years ago, which is a fair timeframe to 
change paradigms of treatment and patient attitudes.  
Concerning pulmonology rehabilitation, it is highlighted that asking as many 
stakeholders in the care flow as possible brings more input; and asking the patient and 







conceptual perception assessment, it is worth including patient and caregiver interviews 
to map the needs of the two most important stakeholders of COPD care in Hungary.  
A systematic analysis of 14 studies demonstrates that self-management reduces hospital 
admissions without deteriorating quality of life parameters (103). An important 
methodological point is highlighted: due to the heterogeneity of the studies, it is very 
hard to set up the optimal education, based on the publications reviewed, but it may be 
tailor-made (104). Finding the right balance between fixed content to keep 
measurements intercomparable is a methodological prerequisite, whilst personalization 
seems to bring the most benefits to the patient.  
Taking the matter of standardization of education content to a national level, data 
providers in Germany present such diversity that prefer not to compare (105). The study 
confirms that these education projects should be either aligned individually or require a 
higher level of coordination for initiation. The most common errors that were found in 
46 of the 95 programs are as follows: evaluation of program success, inadequate 
transparency of cost data and the lack of the same in quality of life interventions. It 
seems clear that success rates should be defined, although there are no consensus or an 
established method (106). A prerequisite for the achievement of success indicators is 
that the patient is actively involved in the therapeutic process and has an individual 
action plan for the self-management of the disease (107). 
Although very softly, (108; 109) also affirm that a caring environment, nice and 
competent words initiate the self-management process in the COPD patient. Once they 
meet such condition, they become more aware of their disease and they are willing to 
do more in their homes. I should highlight the importance of “trial and error” effect in 
patient care: the more patients try, and get conscious about the disease, the more 
positively they think about the future and disease outcomes.  
A holistic summary of patient education opportunities (110) include printed brochures, 
recorded videos and audio-visual materials, self-education, self-monitoring, self-
directed therapy, patient involvement in therapy, patient interviews on side effects, 
organization of self-help and therapy groups, telemedicine, computer and internet 
patient information, targeted interventions to improve health literacy in disadvantaged 







process: media and telemedicine should be the future direction, since it also corresponds 
with the limited availability of healthcare providers.  
Another Canadian patient education project (111) covered adherence, inhalation 
techniques, health-related quality of life, and the use of health resources such as drug 
therapy and COPD exacerbations. Content included explanation of the current therapy, 
dosage, administration, patient expectations, duration of therapy, and potential 
outcomes, and follow-ups and improved inhaler use. By the “teach it back” strategy, 
understanding the components of adherence caused by a lack of knowledge and the 
patient’s perceptions of the disease have helped to enhance adherence. 
An analog of this study (112) examined COPD self-management on n=176 patients, 
with the following education content: COPD status, medication, and respiratory 
training. The Morisky questionnaire was used to measure adherence, and COPD 
Knowledge and SGRQ were used to measure quality of life (6 and 12 months follow-
up). The article states that the success of COPD therapy depends on m education by 
10% and by 90% on education. 
Education should be structured to ensure that the measurements are inter-comparable. 
The education should consider the patients’ capabilities, so that the content can be 
acquired, and it has cost-effective long-term effects: less frequent exacerbations result 
in decreased use of healthcare resources (113). 
The following studies were implemented in the community pharmacy setting. For the 
role of the pharmacist, the following key areas have been identified (114):  
(1) primary prevention: campaigns, lifestyle counseling, awareness raising;  
(2) early diagnosis;  
(3) management and ongoing support: pharmacist care, information on 
inhalation device use, disease outlook, dosage, self-management of the 
disease;  
(4) overview and follow-up: monitoring adherence and device use. This 
connects to the content of the community pharmacy pillar of our education, 
and we considered these points to define the potential role of the pharmacist 







Inhaler use and follow-up in the community pharmacy setting were studied in 55 
community pharmacies, with n=747 patients (115), using a 21-item questionnaire. 
78.9% of patients made at least one mistake while using the inhaler, and dropped to 
28.3% in the 4-6 week follow-up after education. This has the implication that the effects 
of education last for 6 weeks, so it is advisable that the follow-ups are planned at least 
for 3 months in a study.  
The Belgian PHARMACOP study (116) shares the methodology of (115) and it is very 
similar to the final study design of our investigations. Altogether, n = 734 patients were 
enrolled and followed for 3 months between December 2010 and April 2011. Adherence 
to maintenance therapy and the use of inhalation devices were the focus of the study, 
and education was provided to patients at baseline and after 1 month. Both variables 
were significantly better in the intervention group, and a significantly lower number of 
hospitalizations were reported. 
Using the in-depth interview method, n=173 patients were reported that the absence of 
depression, comorbidities, and patient perception of the disease have a much greater 
impact on adherence than demographics or disease severity (112). HBM (Health Belief 
Model) is a validated scale to evaluate patient beliefs and perceptions. Doctor’s 
perceptions were examined, where the mention the following major symptoms: 
shortness of breath, fatigue and cough (117). 
Another interesting insight, with a final research design similar to the one presented in 
this study affirms that according to semi-structured interviews with a representative 
sample of 34 patients of varying COPD severity, the four topics that were mostly 
mentioned by patients are the effects of symptoms, coping strategies and challenges, 
and areas needing support (118). The biggest challenges are the psychological impact, 
mental rejection of diagnosis and / or progression, impact of comorbidities and 
inadequate self-management skills. Patients demonstrated a need for assistance, and 
preferred non-pharmacological interventions.  
The role of the relatives, especially the one of the spouse has been described (119), and 
it may be worth considering involving them in patient education. In the Hungarian 
context, it seems realistic approach that accompanying relatives are keen to learn about 







interesting idea. The same person could help a lot in constructing the inhaler (111), 
which may create a more favorable environment for adherence, too.  
1.3.4. Quality of life, social context and coping strategies 
A very interesting approach is that the COPD patient is asked about their expectations 
about the therapy, which is a modern way to self-determined PROs. The following main 
needs were accentuated by n=144 patients: breathlessness (64.6%) cough (13.9%), 
sputum production (11%), and exacerbation (8.3%). Self-improvement in PROs did not 
correlate with CAT score, but was significantly significant with FEV1 (77). Based on 
how patients relate to their condition, it seems to be a conclusion they are more 
symptomatic than exacerbating, and this is reflected by their perceptions, too.  
The effects of patient education demonstrated benefits the following parameters 
(n=941): frequency of referrals to rehabilitation, quality of life, psychological and 
individual parameters such as FEV1, inhalation technique, smoking status (120). It 
should be noted that a non-validated quality of life scale and more qualitative individual 
parameters were used to evaluate the impact of education.  Patient education with a one-
year follow-up shows an inconsistent effect on HRQoL score (121), with one-third of 
patients significantly improving by the time of repeated patient education, although the 
effect on the population as a whole was small. The implication it has is that subgroup 
analyses might reveal further insight into the benefits to the patient, since different 
subgroups may show altered susceptibility to education.  
The description of the methodology of Swiss national QualiCCare program was an 
interesting input to designing my research (122). Prior to the program, the Swiss 
population was estimated to have bad parameters in COPD care in international 
comparison. The study was conducted between 2013-14, and randomization was 
performed at the level of the GP. The selection criteria for the study were left loose: 
COPD diagnosis, former or current smoker, no other lung disease, no asthma and no 
hay fever, good German. The primary endpoint was to improve the quality of 
“treatment”, but the secondary endpoint included a number of other aspects: referral to 
and participation in rehabilitation, written action plan, proactive follow-up, CAT score, 
and assessment of treatment quality by the GP. Overall, it seems that the study focused 







For methodological reasons, it is worth looking into the CEGEDIM study (123), which 
uses SF12 as a general quality of life questionnaire and SGRQ as disease-specific one, 
and includes seven countries. The French subgroup analysis highlights the role of 
physical activity: it is worth paying special attention to this aspect, as reduced function 
may lead to further impairment and the effect of movement on the airways may improve 
COPD symptoms. The same idea is supported by (124), which adds a further 
recommendation that these activities should be supervised.  
1.3.5. Adherence 
The relationship between COPD and social stratification is examined in a Danish study 
(125), with data from n=13,369 patients, using proportion of days covered (PDC) to 
quantify adherence. Interestingly, only 32% of patients were found to have poor 
adherence (PDC = 0.8) and 5% did not use any medication (PDC = 0). The analysis 
showed lower adherence among lower income earners, the unemployed, immigrants and 
single people, and a positive association between low education and exacerbation and 
hospital admissions. The unemployed and those living alone were less likely to have 
exacerbation but higher death rates. The study introduces the concept of “health equity” 
as a priority in the healthcare system; and wishes to identify socioeconomic inequalities 
in the treatment of COPD. Besides this, the major reasons of non-adherence are 
identified (126): inhaler not used (20%), forgot to use (19%) and cost (15%). 
A relationship between adherence and demographic characteristics was found in (127), 
where older age, lower levels of education, and lack of instruction in use were found to 
be the most important errors regardless of device. Malpractice can be observed at all 
levels of care and, but the above groups are especially at exposure of low adherence.  
An interesting series analysis between 2008 and 2012 is the Italian SIRIO study (128), 
which aimed to demonstrate the economic burden of COPD. Economic issues are 
closely related to adherence indicators, as non-use of the drug increases the risk of 
exacerbation, which proportionally increases direct health costs, where one third in 
volume is spent on hospitalization (129), besides the hardly quantifiable additional 
burden on the society (number of lost working hours, salary of hospital worker, unpaid 
tax).  In n=275, predominantly male patients it found that approximate treatment costs 







pharmaceutical costs EUR 499, indirect costs EUR 358, the total direct costs accounted 
for EUR 2,932 euros and the social costs 3291 euros. The following three actions can 
be made to reduce social burden (129):  
(1) organizing national prevention campaigns and disseminating information on the 
disease;  
(2) continuous training and education on obstructive pulmonary disease, 
dissemination of recommendations; 
(3) ensuring access to basic services.  
Considering the cost, the severity of the disease must also be taken into account, since 
the more severe the patient's condition; the more it will cost (130). Consequently, early 
detection and continuously available care is an important task of the health system. 
Non-adherence rate in COPD is described in completely different ranges: 34% of 
patients did not use all of their prescribed medications at admission and 53% did not use 
the correct dose (131), which implies that adherence rate can be vastly in different 
geographical settings. As of education content, the study supports the idea that patients 
should be taught about the correct dosage and the types of medication (maintenance 
therapy, reliever).  
Patient beliefs and perceptions should be evaluated when designing a study (132), which 
connects to (133), which describes a progressive and complex patient education and 
adherence monitor system. The first step was disease-specific education and it was 
followed by drug prescription control at the pharmacy. Primarily, I wanted to include 
monitoring dispensing data as an additional method to double check adherence, I could 








1.4. Overview of scales and aspects of selection 
During the study, I measured the patient reported outcomes (PRO), which I interpreted 
in accordance with relevant literature (134). Both single and multi-item questionnaires 
were used in the study to accurately measure and understand test parameters. The 
examined data were chosen to have both qualitative and quantitative parameters, thus 
recording the patient’s subjective complaints and, where the patient reported such, 
comorbidities. As our sample is not representative in this respect, I left this analysis on 
a qualitative level (there are certain limitations which did not enable me to quantify this 
part of the research). However, when filling in the questionnaires, we put emphasis full 
completion of the tests to get quantitative data. 
The study applies the following four types of scales: 
(1) The nominal scale was used in the demographic questionnaire (eg. gender, 
smoking status). The data was coded in numeric form to facilitate processing 
(eg. active smoker 1, no smoker 0), this is called binary or dichotomous 
classification (134).  
(2) I used an ordinal scale to evaluate the level of education in three groups (primary 
1, secondary 2, upper 3), which can be used to set up an “order” related to the 
educational status of the patients.  
(3) The interval scale does not have a fixed starting point; it evaluates differences 
and intervals in relation to each other. Although the symptomatic score (CAT) 
of a given patient would initially be an ordinal scale, the change in it that is 
monitored by follow-up can be considered as interval (eg, 2 points to 3, over 3 
months).  
(4) Absolute scales have an initial (zero) point, and they give a definite numerical 
value (like the absolute value of CAT symptom scores). Overall, interval and 
proportional scales can be classified as qualitative, while the nominal and ordinal 
scales are the qualitative measures (134).  
In the quality of life tests, we measured utility, which is a commonly measured health 
economics parameter. Given the desire to get quantifiable data besides the qualitative 







utility measurements are the standard game, the time bet and the proportion scale, and 
all scales we used belong to the indirect group. 
Validated scales are available for both quality of life and adherence, so I had to consider 
which one to select for this study. Below I review the aspects of this choice and the 
options available. 
1.4.1. Demography 
The demographic scale in this study is not validated; I created it in order to enable the 
creation of major demographic subgroups. The questions were chosen so that the sample 
is sufficiently separated, that is, to have a sufficient number of groups, but not too many, 
because there would be too few patients in each group to reach statistical significance 
(taking the overall n=118 patients enrolled in the study, this means 3-4 categories for 
each). After completing the informed consent form, patients were allocated a unique 
identifier to keep their personal data safe and to render the study anonymous. Each 
response was numerically coded, thus numerical values were used to record information 
about place of residence, age, gender, (previous) occupation, education, self-reported 
social status, smoking status, pulmonologist and GP satisfaction. 
1.4.2. Quality of life and symptomatology 
The literature offers a wide range of quality of life questionnaires, so there is no reason 
to develop new ones. To make the study comprehensive, the scales should meet the 
following criteria (ie. the questionnaire was chosen if it met the below categories, 
otherwise I kept searching for a new solution): 
(1)  general and a disease specific (by disease specificity I looked beyond other 
respiratory diseases, and wanted to have one that is specific to COPD); 
(2) scientifically recognized and methodologically supported (demonstrated by 
literature data); 
(3) cost-effective or free for academic use; 
(4) easy to fill for the patient; 
(5) should not exceed 20 minutes of administration time.  
Certainly, there is no such as an “ideal” scale, the standards should be set by study design 







questionnaires have the greatest positive evidence (136), which underlines the 
importance to use such a questionnaire. 
General quality of life scales measure the general condition, physical and mental status 
of the patients. Based on the five requirements stated above, I have considered the 
following scales: 
(1) Sickness Impact Profile and Quality of Well Being questionnaires contain the 
most questions and take more than 20 minutes to complete, so I have excluded 
them. Since these exceed 20 minutes of administration, they would not be 
preferred neither by patients, nor educators, because so much time cannot be 
spent on 
(2) The Nottingham Health Profile and the Medical Outcomes Study 36-Item Short 
Form Health Survey appeared to be more favorable at the beginning, though the 
abundance of questions (36 and 38, respectively) would have been confusing for 
the patient, so I excluded them.  
(3) SF-36 could have been a very appealing choice, because visual analog scales are 
very easy to fill in and to understand. This feature is offered by the EQ-5D, 
which comprises the general scale and the visual analog scale in itself.  
(4) Finally, EQ-5D-5L questionnaire was chosen due to the widespread use in other 
studies, and it is easy to administer due to the Likert scale (indicate on an 
ascending scale of four how they feel), and has the benefit to offer the visual 
analog scale (0-100 unit “thermometer”), too.  
For disease specific questionnaires, the golden standard Saint George’s Respiratory 
Questionnaire (SGRQ) is so extensively used in the literature (137) that even though it 
is very extensive, and time consuming to (self-)administer, I decided to use it. 
Furthermore, the IP owner granted the license with no charge for this study. In addition 
to SGRQ, the Seattle Obstructive Lung Disease Questionnaire was considered; although 
one disease specific scale already covers the areas I wished to investigate.  
For symptom assessment, the consecutive educations of GOLD propose two types of 
scales: modified Medical Research Council Questionnaire (mMRC) and the COPD 
Assessment Test (CAT). The mMRC is much shorter but it does not provide any 







and physical activity. Although breathlessness in indeed a leading symptom, the patient 
may be symptomatic for other reasons (cough, expectoration, insomnia), which are 
incorporated in CAT. CAT examines symptomatology on eight questions, where 
patients put their level of exposure on an ascending Likert scale of five. Additionally, 
CAT is reported to yield the same results, no matter if self-administered, or assisted 
(138).  
1.4.3. Adherence 
The following methods have been identified to measure adherence in general (139):  
(1) Indirect methods: mass measurement of inhaler, drug use on a self-declaration 
basis, questionnaire, electronic monitoring, assessment of inhalation technique,  
reading a drug counter or counting pills, monitoring pharmacy dispensation data, 
patient diary, interview with the patient 
(2) Direct methods: biological test 
Given the non-interventional nature of the study, I found it best to include a 
questionnaire to monitor adherence at all measurement points. The advantage of this is 
that the patient administers the questionnaire alone or assisted, which ensures that all 
questions are answered based on the immediate viewpoint of the patient, assistance is 
available if there are any points to clarify, and we have a written document for each 
measurement point. 
A general characteristic of the adherence scales I examined is that they are much less 
complicated than quality of life scales. Since they do not contain many questions, an 
internal benchmark I set that the selected one should meet the following criteria: 
(1) less than 10 questions, consequently, easy to administer (>10 minutes); 
(2) scientifically recognized and widely used; 
(3) available free of charge for academic use or a license is granted in a cost-
effective way (except for MMAS-8, which was not completely free, though a 
significant waiver was granted); 








Looking into a review on the adherence tools (140), there is an abundance of available 
scales, though their use is not that standardized as the one of quality of life scales. MAQ 
(Medication Adherence Scale) is a relatively often used scale, which identifies (non-
)adherence dimensions (140): medication habits, adherence limitations, and medication 
beliefs. Interestingly, it states that non-adherence as a fact is much more studied that 
underlying behavior and factors that trigger non-adherent attitudes. This study suggest 
that before selecting the scale, patient characteristics of the sample should be considered.  
A broad list of adherence scales is available in the literature (141). Contrary to the name 
of the Brief Medication Questionnaire, its administration cannot be implemented too 
fast, since medication should be administered in each case (this is an information the 
patients themselves might not be aware of); and the range of patients it was validated 
for included subjects suffering from diabetes and depression.  
I also dropped the Hill-Bone Compliance Scale because of the inadequate disease profile 
(validated for subjects with hypertension). From the design point of view, the Self-
Efficacy for Appropriate Medication Use Scale seemed lengthy as it provides 13 
questions and 3 Likert-scale answers. Due to its methodology and its desire to include 
disease-related beliefs, the Medication Adherence Report Scale (MARS) scale was an 
appealing option; however, internal consistency data are not yet available, and the scale 
itself was originally designed for schizophrenia patients, so its use in chronic diseases 
is still questionable.  
Finally, thanks to its comprehensive and widely accepted literature, I chose the MMAS-
8 scale for the study. The license was granted at available price for this study, and the 
scale itself is easy to administer (eight yes/no questions with one inverse question), and 
easy to process and evaluate. By definition, good adherence is 8 points, medium 
adherence between 6-8, and low adherence below 6. A limitation of this scale is that it 
focuses on drug intake, which is associated with MPR (medication possession ratio), 
and does not consider beliefs and perceptions extensively. However, despite these 
relative shortcomings, I found this scale to be the most suitable for participating in the 
study. The 8-question version is the latest, most sensitive and specific version of the 
questionnaire, and the addition of 4 additional questions allowed for further refinement 







(142). Please consult Table 5 for a complete overview.  







MMAS-8 yes [license 
granted with 
discount] 
good adherence: 8 
points, medium: 6-8 
points,  
low: <6 points 
ca. 10 min 8 questions to measure 
medication adherence  
EQ-5D  
+ VAS 
yes utility is calculated 
based on patient input 
on a Likert scale, the 
higher the value the 
higher the utility 
ca. 10 min generic quality of life and 
snapshot on current health 
status 
CAT yes asymptomatic: <10 
points symptomatic: 
>10 points 
ca. 8 min 8 questions to assess 
symptoms on a scale of 0-5 




based on patient 
input, impact, activity 
and total scores are 
calculated, the higher 
the value, the worse 
health status (inverse 
relationship) 
ca. 25 min comprehensive appraisal 











2.1. Mission statement 
The main goal of the dissertation is to provide guidance on the ideal patient education 
content, validate it in a real-life setting, and to elucidate its effect on patient-related 
outcomes. As for adherence, an adherence appraisal cystic fibrosis was also targeted.  
In a stepwise approach, the following objectives were set (Figure 6 is a graphic 
overview of the objectives scheme): 
2.1.1. to assess the attitudes of two key players (patient, physician) in COPD patient 
care. This new methodology should be reproducible, widely applicable, and 
personalized & understandable to patients.  
For the pulmonologist interviews, I set the following project specific objectives: 
- to develop a patient education program that is based on the expert opinion 
of pulmonology therapists who play a key role in the care of COPD patients; 
-  to understand the perceptions and attitudes of the pulmonary therapist, and 
to gain a comprehensive landscape of patient and condition, the success of 
the treatment, and their relation to adherence; 
-  to assess the potential of improving patient adherence in outpatient care, 
rehabilitation and hospital settings. 
For the patient interviews, I set the following project specific objectives: 
- to assess the opportunities of COPD disease management in the community 
pharmacy setting; 
- to understand patient attitudes, perceptions, fears, beliefs that affect the 
everyday life of patients; 
- to create a local good practice and to investigate how the community 
pharmacy pillar of integrated care can work in the context of Hungary.  
2.1.2. to conduct pilot studies to determine the optimal scenario to go live with the 
education project; 
2.1.3. to investigate the effect of education on quality of life and adherence of COPD 
patients at different study sites (Budapest and the countryside) by a different set 







2.1.4. to propose the ideal conditions of education (pharmacist care in the 
community pharmacy setting or pulmonologist care in the outpatient setting, 
assisted by a nurse); 
2.1.5. to understand the background of adherence in a wider context of pulmonary 
conditions, including the different setting of cystic fibrosis. 
 
Figure 6: Overview of the research objectives 
2.2. Hypotheses 
2.2.1. Patient-centered education content can be developed based on the attitudes and 
perceptions of pulmonologists and patients.  
2.2.2. This education content has a positive impact on medication adherence and 
quality of life, and this demonstrated by validated scales.  
2.2.3. A methodological overview to broaden the scope with CF medication adherence 
will help me reveal more about adherence patterns and patient attitudes in 
respiratory conditions.  
Follow-up & CF research 
Follow-up at 3 months' visit and investigation of 
long-term impact
Adherence considerations for COPD and outlook 
to another respiratory condition: cystic fibrosis
Development of education and implementation of the NIS
Suggestions to the ideal education content 
(mapping & literature review)
Inclusion of patients in pulmonology outpatient centres 
in district 19 and 13 of Budapest, Vác and in a 
community phmaracy setting in Göd
Mapping
Inclusion of pulmonologist expert opinion by 
mapping their attitudes and perceptions








3.1. Attitudes and perceptions 
3.1.1. Pulmonologists 
We interviewed 20 pulmonologists who are involved in the care of COPD patients; they 
work in outpatient centers, hospitals and rehabilitation centers. An interview lasted 30 
minutes and we examined three clusters of questions. Table 5 details the topics of the 
methodological blocks. It is important to underline that the order of these is in line with 
the objectives of the study but may differ from the one of the interview blocks. 
The interviews were prepared by a mixed method and recorded in writing. In addition 
to the semi-structured groups of questions, I tried to allow more space to physicians’ 
views to develop, resulting in an overall shift towards in-depth interviewing 
methodology (143). We focused primarily on developing their own thoughts and 
perceptions, and in each case, we also recorded the specific terms used by the pulmonary 
therapists. 
Table 5: Pulmonologist interview methodology 
Aim Topic Sample questions 
1 Educational program How do patients experience COPD? What bothers them the most? 
What does an ideal training program look like for your patients? 
What key elements would you mention to teach the patient anyway? 
What does doctor-patient collaboration mean to you? 
What can pulmonologist, a GP, a pharmacist and an educator do? How? 
2 Patient characteristics 
and pulmonologist 
perceptions 
What are your experiences with COPD patients in the outpatient centers? 
How many of 10 patients have already been diagnosed with COPD? 
What condition do your patients have? 
What is your main motivation for treatment? 
How would you describe a typical COPD patient? 
What is a good treatment? 
3 Adherence & its 
improvements in the 
pulmonology 
outpatient centers 
What do you think most influences the patient’s cooperation? 
How to choose an inhaler for the patient? 
Who can decide on the inhaler? What are the aspects of pharmacy 
generic substitution? 
What methods do you use in pulmonary practice to promote patient 
adherence? 









3.1.2.1.  Study context 
Göd is a medium-size city with around 19,800 inhabitants (144). According to the 
Rotterdam Study (33), COPD prevalence is 4.6%, so 5% seems to be a rationale 
approximation in a European setting (2). This means that the overall COPD population 
of Göd should be around 95 people, out of which, N=6 were included in our study (7%). 
Inczeffy Pharmacy is a central and well-known community pharmacy in the city, and it 
has gained an innovative reputation due to their commitment to patient education 
programs.  
3.1.2.2.  Inclusion of study participants 
During dispensing medication, patients with the J44 ICD classification code were 
offered to participate in the pilot project. Altogether, patients were screened for 5 
working days; 25 showed their interest and eight were willing to participate in the 
education session, and finally six patients showed up. 
3.1.2.3.  Interview methodology 
We performed exploratory in-depth interviews with the patients (145). The structure of 
the interview has been designed to determine the key elements of a patient education 
program based on patient input and needs; so the major aim of the interviews was to 
explore their needs as of education content (146). Table 6 provides an overview of this 
structure and an insight into the explorative questions. One interview lasted ca. 30 
minutes. The methodology showed some mixed features with a loose semi-structured 
interview, since we had previously set the major topics we wanted to direct patients to. 
Altogether, we interviewed them by using the active listening technique, which means 
that we concentrated on their thoughts and let them relatively freely talk about their 
condition. At the end of the interviews, patients participated in an educational session 
(prototype education) where they could ask freely about their doubts related to their 








Table 6: Interview methodology guide corresponding to the objectives of the study 
Aim Topic Sample questions 
1 In-depth interviews to understand 
patient attitudes, perceptions 
How do you feel about your disease? 
What disturbs you most in COPD? 
What would you like to do if you could breathe 
freely? 
Do you think your condition will get any better? 
What does a regular day of yours look like? 
2 Explorative interviews for educational 
content & insights to adherence 
Do you have any questions related to your 
condition? / What would you like to know about 
it? 
What have you heard about it? 
Can you tell us how to use these inhalers? 
What would you like to change about the 
condition? 
Do you believe that you / the doctor / your 
educator can make a change? How? 
3 Creating local good practice in Göd How can the pharmacy staff be engaged? 
How can we engage local stakeholders to keep 
up with the project? 
3.1.2.4. Symptom assessment 
We invited the patients to self-administer the COPD Assessment Tool (CAT),3 which is 
a standard method to assess symptomatology in pulmonology practice (147). CAT is an 
8-item questionnaire to assess their symptoms on an ascending scale until 5, and scores 
range 0-40. Patients are considered symptomatic above 10 scores. 
  
 
3 We fully complied with the guidelines at https://www.catestonline.org, and we solely used the licence 







3.2. Impact of education on quality of life and adherence  
3.2.1. Study design 
This non-interventional, multicenter, longitudinal study was conducted between March 
2016 and February 2017 at three pulmonology outpatient centers in and around 
Budapest, Hungary (district 13 and 19 in Budapest and Vác). Study subjects were 
patients visiting the center, having an established diagnosis of COPD by a 
pulmonologist, and providing an informed consent to participate in the study. Subject 
recruitment was random in the sense that every tenth patient visiting the center for 
consultation was invited to participate in the study and if eligible and providing consent, 
enrolled. In case the tenth patient was ineligible or refused consent, the next patient was 
invited and so on until a subject was recruited. Study subjects underwent two study visits 
– one at baseline and the other at follow-up approximately three months later. At 
baseline, subjects’ sociodemographic and medical data was collected, subjects were 
asked to fill in the adherence, symptom perception, and QoL questionnaires (described 
below), and patient education was provided (described below). At the follow-up visit, 
subjects were asked to fill in the same questionnaires again. Subjects’ education level 
was assessed on a scale of three, ranging from basic to university level. Social status of 
the subjects as well as their perception on certain outcomes were self-reported as given 
in Table 9.  
The study was conducted in accordance with the principles stated in the Declaration of 
Helsinki (1961) and its subsequent revisions, Good Clinical Practice guidelines, as well 
as national laws. Prior approval of the study was obtained from the Semmelweis 
University Regional and Institutional Committee of Science and Research Ethics 
(241/2015).  
3.2.2. Inclusion criteria 
Patients who had a diagnosis of COPD and signed a patient consent statement were 
selected for the study (see Figure 7 for a summary). Patients with the below conditions 
were excluded from the study: 








(2) other untreated chronic conditions that affect quality of life (heart failure, 
pulmonary fibrosis, ischemic heart disease); 
(3) exacerbation within less than 3 months; 
(4) acute respiratory disease or tumor at the time of screening. 
Figure 7: The study enrollment process 
 
3.2.3. Patient education 
Nurses or pulmonology assistants who had been previously trained to instruct subjects 
using the standardized content conducted patient education, based on a fixed content, 
face-to-face on an individual basis. Subjects were encouraged to ask questions and 
provided with take-home lessons at the end of the session. By keeping the content same 
for all study subjects, we ensured uniform patient education, although by answering 
subjects’ questions we also allowed for an individualized approach (please consult 
Figure 8 for more details in patient education).  
Education provided during personal meetings were reiterated through a short leaflet, 
which subjects took with them (please see its content in attachment). Information 
contained in the leaflets was based on that provided by pulmonologists in a previous in-
depth interview as well as systematic reviews (97; 148; 149). The leaflet contained the 
















provided information on COPD and symptomatic alterations in the lungs and identified 
the present type and state of the subject’s COPD. The treatment block contained 
information about use and medications such as short-acting BAs and MAs to prevent 
exacerbations, correct technique for inhaler use, and symptoms of and actions to be 
taken in case of exacerbations. The third block informed subjects about smoking 
cessation, breathing techniques in case of shortness of breath, physical exercise, and 
lifestyle modifications (please consult Figure 9 for more details on the study flow).  
 
Figure 8: The patient education methodology 
3.2.4. Assessment questionnaires 
Quality-of-life scales were selected in accordance with currently employed general and 
disease-specific algorithms (15; 148; 150). For adherence, we used the Morisky 
Medication Adherence Scale (MMAS-8) which has been validated for chronic disease 
conditions as well as COPD (22; 151). 
Each study subject was provided with a standardized questionnaire at enrolment and at 
follow-up. The questionnaire included three QoL algorithms designed to assess general 
and disease-specific QoL and one adherence algorithm. Wherever possible, validated 
Hungarian versions of these algorithms were procured and used with the written 
permission of the holders of the intellectual property of the same.  
first session with 
fixed content
•Patients administer the surveys with assistance if needed
•Education is provided individually, patient receives a brochure
standardized 
education
•Duration: ca. 20 min
• fixed content with key areas
• face-to-face
•verbally presented by the educator (usually: nurse)
follow-up
• Patients administer the survery with assistance if needed
• Individual questions are answered







3.2.5. QoL algorithm 
3.2.5.1.1. Generic measurement tools: EQ-5D-5L and EQ-5D-
VAS 
The EuroQoL-5D-5L measures five parameters related to health: mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression, each on an ascending scale 
peaking at 5 (152). The visual analog scale (VAS) allows the patient to indicate their 
current wellbeing on a scale of 0-100. Values on these scales range from 0.281 to 1.000, 
with higher values indicating better QoL (153; 154). 
3.2.5.1.2. Disease-specific measurement tools: SGRQ and CAT 
The St. George’s Respiratory Questionnaire (SGRQ) is a comprehensive scale that 
measures symptoms, activity, and impact scores (155). Questions 1-8 relate to patient 
recollection of their symptoms in the preceding period while questions 9-16 inquire 
about the patient’s current state on which activity and impact scores are calculated. The 
SGRQ scores range from 0 to 100, with lower values indicating better QoL and a 
reduction of four units is generally taken as a clinically significant improvement (74). 
The COPD Assessment Tool (CAT) is an 8-item questionnaire for assessment of 
symptoms. Patients rate their symptoms (cough, phlegm, tightness in the chest, etc.) on 
an ascending scale until five. Scores range from 0 to 40 and higher scores indicate higher 
severity and debilitation in patients (156). 
3.2.6. Adherence algorithm 
The eight-item MMAS-8 (157; 158; 159) has been widely used and recently validated 









Figure 9: The study flow chart 
3.2.7. Sample size calculation and data analysis 
While calculating sample size we operated on the assumption that at least 10 subjects 
per variable would be required in order to achieve the primary objective and impart 
enough power to the study (160). Practically, this was performed in such a manner that 
every tenth patient in the pulmonology outpatient centers was offered to participate in 
the study, once they met the eligibility criteria. This helped us randomize the patients 
who participated in the study, and we provided equal access to education vs. standard 
procedures.  
Moreover, we also considered adherence (MMAS-8) and COPD symptomatology 
(CAT) scores to be important markers for us to be able to distinguish the effects of 
patient education, because these are presumably able to detect changes in patient status 
besides the known correlation between education and adherence. At the same time, the 
other questionnaires were handled with the same care, though initially we assumed that 
these are primarily for detecting minute changes.  
Bearing these requirements in mind, we estimated that a sample size of approximately 
100 subjects would be sufficiently large to yield statistically significant results and 
achieve the research objective, and finally n=118 questionnaires were sufficiently 
screening
•Study centres identified: Pulmonology outpatient centres in Budapest XIX., XIII., 
Vác, and Inczeffy Pharmacy in Göd
•Inclusison criteria checked, eligible patients enrolled
baseline
•Baseline QoL and adherence values are taken
•Education was provided, and the patient goes home with a brochure, continues 
living their life
follow-up
•After 3 months, patients take the same QoL and adherence scales 







recorded and checked to be included in the study. Altogether, eight questionnaires 
should be excluded from our analysis; because the missing answers would have made it 
impossible to provide the desired accuracy to be considered as valid, whilst the exact 
number of missing questions was determined in accordance with the evaluation guides. 
Based on the results of the pilot study, patients are more keen to fulfill paper-based 
questionnaire, so all of them were printed, allocated, and administered by the patient, 
and where possible, with assistance. Data were digitalized in Excel; numerical 
transformations took place to enable SPSS analysis. Then, we analyzed data using IBM 
SPSS Statistics version 22.0. Serialization of data enabled us to quantitatively analyze 
them, so quantitative variables were evaluated by paired-samples t-tests and mixed-
measures ANOVA (demographics, all single input data, like quality of life and 
adherence scores), and ANCOVA to study temporal effect (ie. the 3 months longitude 
of the study). For study the effect of independent variables such as age, education, etc., 
we used the t-test, one-way ANOVA, and mixed-measures ANCOVA. Furthermore, we 
employed correlation analysis to compare baseline data to the follow-up data, as well as 
for multiple comparisons of the changes of a single value vs the change of another value. 
Results were considered significant at P <.05, and we also noted the tendencies, 








3.3. Background of adherence in a wider context  
A systematic literature search of English-language articles was conducted in April 2015 
using Medline and Embase (via Scopus) with the following search terms: (adheren* OR 
persisten* OR complian*) AND (“cystic fibrosis” OR muscoviscidosis) AND 
(“Pseudomonas aeruginosa”) AND (antibiotic*). No publication date limits were 
defined. The search results were processed in two steps: first, the titles and abstracts 
were screened; next, all the full text of all the potentially relevant articles were analyzed. 
The references of the included articles were screened for additional eligible studies. The 
literature screening was conducted by two independent reviewers; disagreements 
between reviewers were resolved by consensus (Figure 10 summarizes the steps of 
screening). The reasons for exclusion in both steps were the following:  
(1) the article reported no new evidence (ie, editorial, letter, case report, or review),  
(2) the article was a case study,  
(3) the article was not related to CF, and  
(4) the article had not assessed adherence to inhaled ABs for the treatment of 
chronic PA infection in CF. This review included only publications in which 
data on adherence to inhaled ABs were clearly separated from adherence data 
of other medications. 
The data extraction was limited to findings relevant to the research topic. The following 
information was extracted from each included study:  
(1) the first author and year of publication,  
(2) the country,  
(3) the study design,  
(4) the study year,  
(5) study exclusion and inclusion criteria,  
(6) the study population characteristics, 
(7) the medication therapy,  
(8) the method of measuring and defining adherence,  
(9) adherence data, and  







In case of studies in which adherence rates were presented graphically only, 
WebPlotDigitizer 3.8 was used to extract numerical data accurately out of figures. The 
scope of this review was to give a systematic overview on the adherence to inhaled ABs 
in CF; therefore, results of adherence measures that were not applied to assess 
adherence to inhaled ABs were not abstracted from the included studies.  
For the quality assessment of the included studies, the strengthening the reporting of 
observational studies in epidemiology (STROBE) checklist (161) was used. Two 
review authors independently assessed all the studies; disagreements were resolved by 
consensus. The results of the quality assessment were summarized as the percentage of 
the fulfilled criteria for each study (criteria that were not applicable to a study were 
excluded from the quality assessment), ranging from 0% (none of the applicable 
STROBE criteria fulfilled) to 100% (all applicable STROBE criteria fulfilled). 
 









4.1. Attitudes and perceptions 
4.1.1. Pulmonologists 
4.1.1.1.The study population 
The in-depth interview was conducted with 20 pulmonologists. The majority of those 
working in the profession are over 50, most of them working in an outpatient center 
(Table 7). According to the Hungarian Society of Pulmonologists (162), there are 540 
active pulmonary physicians in the country, almost 50% of whom are over 55 years old. 
The interviewees were selected so that their distribution by gender, age, and workplace 
corresponded to that of Hungarian pulmonologists. About 4% of the total sample stated 
during our interviews (see Table 7 for further details). 
Table 7: Gender, working affiliation and age of pulmonologists 
      % 
  total number 20   
gender male 3 15% 
  female 17 85% 
main 
affiliation hospital 7 35% 
  outpatient center 12 60% 
  rehabilitation 1 5% 
age under 40  3 15% 
  40-50 8 40% 
  over 50  9 45% 
4.1.1.2.Patient characteristics and pulmonary 
physician perceptions 
We asked the doctors to characterize the COPD patients they care for, to mention signs 
and observations from which they can immediately determine that they are dealing with 
a COPD patient. Many similar elements appeared “smoker”, “under-socialized”, 
“coughing”, “breathless”, “slow”, “older”, “and male”. Separation according to the 
textbook types of emphysema / bronchitis was also observed. One of the two types of 
lung therapist figuratively described this as "the thin, lean and smoking”, the “dry” type, 
and the “sputumy, corpulent, puffy” who is more “sputulent”. One of the interview 







promotion in the previous decades. This emancipation focuses primarily on Budapest 
and its surrounding area, where COPD patients are evenly distributed gender wise. The 
disease is also associated with a socioeconomic gradient: patients are less socialized, 
with more men than women in the countryside, as women are more likely to get with 
the more “chic” diagnosis of asthma (see Table 8 for more patient characteristics).  
Table 8: Major characteristics of the COPD patient  
(values are created as of their occurence in the pulmonologist interviews) 
Coughing, breathless, sputum, slow 68,4% 
Smoking 63,2% 
Lower social status 31,6% 
Male 26,3% 
Over 50 years 26,3% 
Lean, thin and improductive cough 21,1% 
Cyanosis 15,8% 
All of them are different / depends on stage 10,5% 
Limited movement, choking feeling upon movement 10,5% 






Figure 11 gives an insight how pulmonologists think about the diagnostical status of 
COPD. The results showed an average of 4.2 patients are diagnosed (standard deviation 








Figure 11: The extent of diagnosedness of COPD and its circumstances  
(axis y: time and reason of appearance in the pulmonology outpatient center,  
axis x: numbers of answers and percentage) 
Pulmonary therapists consider awareness raising important, as there are many 
undiagnosed patients. Patients appear for consultation at a later stage, and only serious 
complaints call their attention to the presence of the disease (see Figure 11). Often, the 
patient comes from a co-order, that is, COPD is found to be comorbid (Figure 11). 
Opinions include the words “complaint”, “respiratory infection”, “FEV1 <50%” and 
“family member bothered (by fatigue / cough)”. Thus, it is the symptom that primarily 
disturbs the patient or a family member and directs them toward diagnosis. “Hard to 
guide”, “needs multiple follow-ups”, has the “worst” adherence – these are the most 
commonly noted expressions. Unlike cardiovascular and psychiatric diseases (163), 
COPD patients have low level of disease knowledge. It contributes to bagatellizing their 
disease, and leads to low motivation to stop smoking or to take the recommended 
therapy seriously. 
Disease acceptance is inadequate: lung diseases are seen as a kind of temporary 
“infection”. Most of the patient also have financial problems, so the therapy focuses on 
the cheapest component, which is reliever medication. There was only one positive 
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time of the diagnosis on adherence, but when he was satisfied with the drug at the second 
encounter, he was more receptive to the therapy. These initially hesitant patients usually 
do not consider their inhaler as a medicine, but refer to it as a "curative pipe". 
4.1.1.3. Adherence and its improvement 
The perception of adherence in COPD is worse than average: patients are considered to 
have low or medium low adherence. Symptomatic patients are more adherent, but this 
effect is temporary: they take the drug only while they are feeling ill (Figure 12). 
 
Figure 12: Adherence levels of patients, characteristics of each group and factors affecting adherence, 
according to pulmonologist expert opinion (numbers and percentages of answers on axis x) 
Subjects interviewed repeatedly returned to disease perception, emphasizing that the 
asymptomatic patient “does not take their disease seriously”, the symptomatic “wants 
some medication”, but they do not feel the connection between smoking and COPD. 
Patients tend to say that they prefer to take the medicine, but refuse to quit smoking. 
Often the environment and air pollution are cited as the cause of the disease. The doctors 
interviewed said, “it is very difficult to start therapy”, “it is easier for patients with 
severe conditions.” 
One view is that it is worth classifying COPD patients according to adherence: there are 
those with minimal adherence (about 60%), with whom no or very limited results can 
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per year). There is a very narrow group of people who belong to the “perfect” adherence 
group (over 10 medication purchases per year, 10%). Another view is that adherence to 
COPD is around 20% and highlights the role of patient education programs that promote 
adherence to the inhaler and its proper use. 
With respect to generic formulations and devices, we have assessed the openness of 
pulmonary physicians to permit the replacement the prescription (with the same active 
ingredient) with a cheaper drug at the pharmacy. Opinions are in consensus: the choice 
of the active ingredient and the route of administration should be kept entirely within 
the competences of the physician, and there is no particular need for a pharmacy inhaler 
substitution. Two interviewees have taken a different view: at the patient’s request, they 
consider switching to another brand if the price is less than two thousand forints. Thus, 
this amount may be a psychological limit that the patient is willing to spend on their 
COPD medication. Another opinion is that pharmacists should have the opportunity to 
do the generic substitution, once the new inhaler technique is taught to the patient. In 
this case, monthly monitoring of patients is needed, and pulmonary therapy should be 
implemented in the pharmacist-GP-pulmonologist triangle (164). Figure 13 provides a 
deeper insight into factors affecting patient adherence.  
 
Figure 13: Doctor-patient relationship, features of the system and the disease and patient 
characteristics to determine adherence (number of answers on axis x) 
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Leading factors affecting adherence are the severity of the disease, the “usability” of the 
inhaler, its cost, disease severity and the physician-patient relationship 
(communication). Two of these are non-variable parameters of the patient (education is 
unalterable, albeit its projection of disease consciousness is alterable; COPD status is 
given, whilst symptom and exacerbation control can be improved), while patient contact 
and communication, and perceptions related to the “usability” of the drug are important 
inputs to the patient education content (Figure 13). Among the factors influencing 
adherence the price of medication and the financial situation of the patient appear; 
however, interviewees less frequently reported this. Interestingly, only one case is 
reported, where the type of the inhaler comes on the first place among the leading factors 
of adherence. 
Understanding the relationship between COPD and smoking also plays an important 
role in the development of disease awareness (35). In education, we have to expect that 
patients are expected to be coming from a lower social scale, less educated, and the 
majority will be men. Symptoms, exacerbation, and family disturbance factor will be 
the cause of the application for pulmonology care. Screening programs will play an 
important role in following up previous smokers or getting new patients to be more 
interested in self-management of the disease (57). 
4.1.1.4. Aspects of the education content 
Interviews describe the following points that I have observed to develop the education 
content.  
(1) Fostering smoking cessation is a priority and should be a priority in the 
program (165; 57); 
(2) Personal education (lung care, hospital or rehabilitation center) is preferred to 
education on the phone (166);  
(3) Content can be repetitive; should include a definition of the disease, symptoms, 
and information on the use of the drug (167); 
(4) It is necessary that the patient be familiar with the language of the education, 







(5) Elements should be like a “fairy-tale”, like a short story to keep the patient 
focused and to let them fully internalize content. 
(6) Pulmonary interviews mention the following content, in order of appearance 
frequency: symptoms & causes, development of the disease, understanding 
therapy, inhaler use, assessment of status, especially exacerbation, 
rehabilitation (the latter includes gymnastics, swimming and relaxation in the 
form of a one-week course). 
(7) Relationship with patients and communication paradigms play an important 
role in the success of the program (169), so we need to gain the patient’s 
commitment from the beginning. During development, this issue is worth 
consideration from both sides: besides patient education, it may be worthwhile 
to initiate a training course where we improve the communication of the doctor 
and thus improve patient acceptance for the disease. One interview particularly 
emphasizes that quality time with the patient is important and equal treatment 
(“partnership”) is needed with the patient (169). 
(8) Patience empowerment and lifestyle have been reported to be included in the 
education – besides patient support emphasizing that the disease did not 
develop shortly, so results can be expected if the therapy is applied chronically. 
Improving patient attitudes is also important for long-term effects (170). This 
aspect was highlighted in all interviews, but along different lines: smoking 
cessation, breathing exercises, control and medication replacement, and 
exercise and weight management.  
(9) Two interviews switch back to medical communication: the doctor should send 
positive feedback, and “celebrate the patient.” If patients accept their illness 
and believe that the inhaler can help, this is the first step on the road to healing 
(171). 
(10) Participation in rehabilitation and the day-to-day implementation of results are 
key to its long-term success (172). 
(11) The inhaler is expected to be easy and quick to learn. It seems important to 
introduce the use of the inhaler in small steps, but both patients and physicians 
are open to new solutions when they see the benefits of the technique (173). 







method easier to accomplish (168). Patients also like to see the effect visually. 
With regard to sprays, lung doctors have noted coordination as a concern, 
where adherence is currently considered the lowest.  
(12) It has also been mentioned that once-daily active agents, although easier to 
administer, if the daily dose is missed, the whole dose is omitted, whereas 
twice-daily agents offer the secure feeling for patients who want to take drugs 
twice a day, and even if one of the doses is missed, the other one can exert the 
effect. Adherence is higher for inexpensive formulations, particularly short-
acting β-agonists, muscarinic antagonists, and their combination formulations. 
In this case, it is supported by their fast onset of action, too.  
4.1.2. Patients 
The community pharmacy setting is a challenging venue for patient education. 
Originally, we intended to incorporate a comparative aspect to a longitudinal study 
which assesses the impact of education on quality of life and adherence; however, 
pharmacy patients turned out to be more willing to be educated in a one-time occasion 
than in a follow-up intervention. Consequently, the community pharmacy pillar to this 
study was halted, whilst the interviews provided patient insight to the education content 
we developed for the further course of the aforementioned study. The patients’ desire to 
get pharmacist advice fast (174), seems to also appear in a German setting, which 
verifies the need for pharmacy disease management projects (patients who attended such 
sessions were enabled to use their inhaler significantly better, although this means 29% 
overall) (175). This idea has been further developed in Japan, where pharmacist-led 
clinics were proven to improve quality of life (176).  
4.1.2.1.  Self-perception and patient related quality of life 
Patients did not mention the textbook like symptoms (sputum secretion, dyspnea and 
coughing) on the first instance; however, they always relate to real-life actions they 
would like to perform: to play tennis, to play with the grandchildren and to paint. 
Falsely, they identify their illness as asthma, and they see no relation to smoking (but 
one patient). They get used to the symptoms, and they mostly perceive them as “they 







should be used when developing the patient profile for the education content; 
additionally, we should use the patients’ own words to help them memorize its content. 
Figure 14 summarizes the implications for the education content. 
 
Figure 14: Major patient perceptions & attitudes and their implications for the development of 
education content 
  
Physical activities and spending time with their family are priorities for the patients. 
The optimal education content should include information on 
improving physical abilities, ensure re-integration to the society 
and provide a caring environment.
Patient education content should be invidualised according to 
the explored needs of the patient, including medication 
knowledge.
Disease awareness, symptoms and adherence
Patients associate their symptoms to "lung asthma", which 
expresses a desire to self-victimisation (and corresponds to the 
fact that they are not responsible for the development of COPD.
They cannnot make a difference between reliever and 
maintenance therapy, and they are unable to recall dosage 
regimens. 
Disease perception
COPD is a consequence of age, and patients see no direct link to 
smoking.
Patients mention actions they would like to still experience, 








4.1.2.2. Medication use and symptoms 
None of the patients was able to identify the reliever drug; even the most asymptomatic 
patient used it every morning, in an inadequate dose. Once-daily inhalers were preferred, 
since one occasion is the frequency everyone declared as adequate for the treatment of 
the disease. One patient reported a willingness to apply alternative methods, namely she 
was interested in herbal drinks as a possible treatment option. The patients were unaware 
of the inhalation therapy they used; hence, there was no apparent fear of steroids. Based 
on their CAT scores, all patients were symptomatic, which implies that they are either 
not compliant, or do not have the right medication. This implies that the patient 
education program should focus on basis elements of medication (reliever and 
maintenance therapy), dosage regimens – and the impact could be evaluated by 
repeated CAT assessment. 
4.1.2.3. Patient attitudes and adherence 
The interviews reveal a truly diverse image of COPD attitudes. The main symptoms are 
feeling powerless and the lack of physical performance. Two patients mentioned 
repeatedly their disability in moving and taking the stairs, and one patient was 
completely confined to oxygen therapy. An important implication of these is that the 
education program should reinforce physical activities, tailor-made to the current 
condition of the patient; furthermore, breathing techniques should be incorporated to 
avoid the abrupt appearance of breathlessness. 
The lack of adherence is a variant, which was challenging to get the patient talk about. 
Finally, they all confessed that they do not either take their medication in the prescribed 
manner, or make changes to treatment regimens upon self-judgement. The better they 
feel, the less they take the medication. The implication of this is that we should make 
sure that patients understand that COPD is a chronic condition, and medications should 
be taken; also in case, they feel right. Interestingly, SMART dosage is available in the 
case of certain drugs, so this is another aspect that should be included in the education 



















































4.2. Impact of education on quality of life and adherence  
4.1.3. Subject characteristics 
We enrolled a total of 118 subjects in our study. The study cohort had a predominance 
of women (n = 70, 59.3%) and an average [± standard deviation (SD)] age of 67.3 (± 
9.4) years (Table 9). A total of 39.8% (n = 47) of our subjects were current smokers. A 
substantial majority of the cohort were urban residents (n = 88, 74.6%) with university 
or high school education (n = 96; 81.4%), and good or above average social status (n = 
103; 87.3%). The self-reported responses of >90.0% of the subjects to questions on 
adherence, the quality of received education, regular check-ups, and trust in their 
pulmonologist were positive. At the follow-up visit, subject adherence to treatment was 








Table 9. Sociodemographic characteristics of and self-reported perceptions of outcomes in study 
patients. 
  n (%) 
Gender 
Male 48 (40.68) 
Female 70 (59.32) 
Age in years, mean (SD) 
Male 68.83 (8.39) 
Female 66.16 (9.91) 
Total 67.25 (9.38) 
Smoking status Yes 47 (39.83) 
Daily cigarette consumption, mean (SD)  11.15 (5.94) 
Residential location 
Urban 88 (74.58) 
Semi-urban 20 (16.95) 
Rural 10 (8.47) 
Education 
University 28 (23.73) 
High School 68 (57.63) 
Basic 22 (18.64) 
Social status 
Good 4 (3.39) 
Above average 99 (83.90) 
Below average 14 (11.86) 
Poor 1 (0.85) 
Adherence to COPD medication vs. other 
medication 
Same or better 113 (95.76) 
Worse 5 (4.24) 
Quality of received education 
Comfortable 113 (95.76) 
Less or more 
comfortable 
5 (4.24) 
Importance of COPD check-ups vs. other check-
ups 
Same or more 117 (99.15) 
Less 1 (0.85) 
Trust in pulmonologist vs. general practitioner 
Better 109 (92.37) 
Worse 9 (7.63) 







4.1.4. Assessment questionnaire performance scores 
Table 10 shows the comparison between baseline and follow-up scores for CAT, 
MMAS-8, EQ5D and SGRQ scales using the paired samples t-test. We noticed an 
overall increase in adherence with mean (± SD) MMAS-8 total scores increasing from 
6.72 (± 1.46) at baseline to 7.01 (± 1.15) at follow-up (t = -2.073; P = .040). With respect 
to severity of COPD symptoms the improvement in CAT scores proved to be non-
significant (t = -0.441; P = .660). There was no significant difference in the QoL (EQ5D; 
t = -0.784; P = .435) and general symptoms (SGRQ; t = -0.063; P = .950) scores between 
baseline and follow-up. Mean scores and comparisons of subscales are also shown in 








Table 10. Comparison of baseline and follow-up scores on self-reporting of COPD symptom, QoL, and 
treatment adherence. 
 Score, mean (SD) 
t(df=117) P 
 Baseline Follow-up 
CAT_Total 16.65 (7.61) 16.9 (7.93) -0.441 0.660 
CAT1 2.45 (1.22) 2.44 (1.13) 0.101 0.920 
CAT2 2.21 (1.38) 2.04 (1.30) 1.860 0.065+ 
CAT3 1.35 (1.26) 1.41 (1.39) -0.531 0.597 
CAT4 3.17 (1.50) 3.08 (1.48) 0.716 0.475 
CAT5 1.90 (1.49) 2.05 (1.58) -1.233 0.220 
CAT6 1.25 (1.51) 1.41 (1.66) -1.149 0.253 
CAT7 1.92 (1.35) 1.86 (1.44) 0.377 0.707 
CAT8 2.41 (1.26) 2.6 (1.13) -1.714 0.089+ 
MMAS-8_Total 6.72 (1.46) 7.01 (1.15) -2.073 0.040* 
MMAS-8_1 0.73 (0.45) 0.75 (0.43) -0.598 0.551 
MMAS-8_2 0.84 (0.37) 0.91 (0.29) -1.806 0.074+ 
MMAS-8_3 0.85 (0.36) 0.89 (0.31) -1.295 0.198 
MMAS-8_4 0.81 (0.40) 0.89 (0.31) -2.404 0.018* 
MMAS-8_5 0.20 (0.40) 0.19 (0.41) 0.323 0.747 
MMAS-8_6 0.92 (0.28) 0.92 (0.28) 0.000 1.000 
MMAS-8_7 0.86 (0.35) 0.92 (0.27) -1.907 0.059+ 
MMAS-8_8 0.74 (0.12) 0.72 (0.14) 1.274 0.205 
EQ5D_VAS 67.41 (16.91) 68.62 (17.42) -0.784 0.435 
EQ5D1 2.08 (1.03) 2.19 (1.04) -1.416 0.159 
EQ5D2 1.27 (0.62) 1.29 (0.67) -0.342 0.733 
EQ5D3 1.72 (0.84) 1.83 (0.95) -1.470 0.144 
EQ5D4 1.87 (0.79) 1.89 (0.87) -0.232 0.817 
EQ5D5 1.54 (0.75) 1.57 (0.84) -0.403 0.688 
SGRQ_Total 37.86 (15.83) 37.79 (17.67) 0.063 0.950 
SGRQ_symp 38.66 (23.85) 37.17 (25.71) 0.825 0.411 
SGRQ_act 52.58 (18.41) 52.34 (18.89) 0.149 0.882 
SGRQ_imp 29.22 (16.26) 29.68 (18.94) -0.332 0.740 
+p<0.1; *p<0.05 
Abbreviations: COPD–chronic obstructive pulmonary disease; QoL–quality-of-life; CAT–COPD 
Assessment Tool; MMAS-8–Morisky Medication Adherence Scale-8; EQ5D–EuroQoL-5D-5L; SGRQ–
St. George Respiratory Questionnaire; symp–symptoms component; act–activity component; imp–impact 
component. 
Highlighted rows indicate covariables that either demonstrate a statistically significant association or a 








4.1.5. Effect of gender, occupation, and education on performance scores 
We also evaluated our data to identify the effects of gender, occupation, and education 
as inter-subject variables on the change in assessment scores. Due to smaller sizes of 
subgroups, we investigated only the main effects while controlling for other independent 
variables as covariates. 
Table 11: Comparison of results for scales (t- and F-values given) for adherence, COPD symptoms, and 
QoL by time, gender, occupation, and education with mixed measures (ANOVA and ANCOVA). 
Effect t F 
df P 
Hypothesis Error  
Adherence      
TIME(2) ∞ MMAS(8) ∞ GENDER(2) 0.103 1.630 7 99 0.136 
TIME(2) ∞ MMAS(8) ∞ 
OCCUPATION(2) 
0.043 0.632 7 99 0.728 
TIME(2) ∞ MMAS(8) ∞ 
EDUCATION(3) 
0.284 2.364 14 200 0.005* 
MMAS_Total(2) ∞ GENDER(2) 0.017 2.013 1 114 0.103 
MMAS_Total(2) ∞ OCCUPATION(2) 0.001 0.074 1 114 0.787 
MMAS_Total(2) ∞ EDUCATION(3) 0.019 1.066 2 113 0.348 
COPD symptoms      
TIME(2) ∞ CAT(8) ∞ GENDER(2) 0.182 3.138 7 99 0.005* 
TIME(2) ∞ CAT(8) ∞ OCCUPATION(2) 0.074 1.135 7 99 0.348 
TIME(2) ∞ CAT(8) ∞ EDUCATION(3) 0.189 1.492 14 200 0.117 
CAT_Total(2) ∞ GENDER(2) 0.002 0.245 1 114 0.622 
CAT_Total(2) ∞ OCCUPATION(2) 0.004 0.372 1 114 0.543 
CAT_Total(2) ∞ EDUCATION(3) 0.034 1.821 2 113 0.167 
Quality of life      
TIME(2) ∞ EQ5D(5) ∞ GENDER(2) 0.024 0.616 4 101 0.652 
TIME(2) ∞ EQ5D(5) ∞ 
OCCUPATION(2) 
0.018 0.461 4 101 0.764 
TIME(2) ∞ EQ5D(5) ∞ EDUCATION(3) 0.062 0.817 8 204 0.589 
EQ5D_Total(2) ∞ GENDER(2) 0.002 0.240 1 114 0.625 
EQ5D_Total(2) ∞ OCCUPATION(2) 0.003 0.306 1 114 0.581 
EQ5D_Total(2) ∞ EDUCATION(3) 0.002 0.121 2 113 0.886 
*p<0.05 
Abbreviations: COPD–chronic obstructive pulmonary disease; QoL–quality-of-life; ANOVA–analysis of 
variance; ANCOVA–analysis of covariance; MMAS–Morisky Medication Adherence Scale-8; CAT–
COPD Assessment Tool; EQ5D–EuroQoL-5D-5L. 
Numbers in brackets indicate the number of the given variable. Time: 1–Baseline, 2–Follow-up; Gender: 
1–Male, 2–Female; Education: 1–Basic, 2–High School, 3–University; MMAS/CAT/EQ5D_Total: total 
scores of scales at 1–Baseline, 2–Follow-up; Occupation: 1–active working status, 2–pensioner; 
MMAS/CAT/EQ5D (X)–where ‘X’ is the number of questions in the specific questionnaire 
Overall, we could not discern any significant association between gender and 







looked at the pattern of individual questions of the questionnaires, and we identified a 
significant difference in two cases. Thus, we discovered that there is a difference 
between subjects based on their education level on the pattern of MMAS-8 scores by 
time [TIME(2) ∞ MMAS(8) ∞ EDUCATION(3)] (F = 2.364; P = .005)., Post hoc t-
tests showed a significant improvement in MMAS-8 scores in patients with basic 
education for questions M4 [t = -2.485; P = .021] and M8 [t = -1.766; P = .046]. 
Differences in pattern of adherence (MMAS-8) by education and time are shown in 
Figure 16A.  
We also observed a statistically significant difference between genders in CAT score 
patterns [TIME(2) ∞ CAT(8) ∞ GENDER(2)] (F = 3.138, P = .005) (Table 11). There 
was no significant difference in scores for any item on the CAT questionnaire in female 
subjects. In contrast, on post hoc analysis we noticed that in male patients, CAT6 
(difficulties in leaving home) scores had increased significantly by the time of follow-
up [t = -1.543; P =.049] (Figure 16B). On comparing the two groups (male vs. female) 
by independent sample t-test, the significant difference in CAT6 scores in between the 
genders was found to be only at baseline. This implies that male patients found their 
symptoms preventing them from leaving their home much less disturbing than female 
patients (t = -2.267; P = .025) at baseline, but by the time of follow-up this difference 
was not detectable (t = -0.159; P = .312). Differences in pattern of COPD 
symptomatology (CAT) by gender and time are shown in Figure 16B. 
To measure the relationship between the changes in the different assessment algorithms 
we used, we created one variable per scale using the ratio of baseline to follow-up 
scores. In most cases, we found the interaction between the changes to be negligible or 
not statistically significant (Table 11). However, there was a weak interaction between 








Figure 17: Difference in pattern of adherence (A) and COPD symptomatology (B) at baseline and follow-
up. 
(A) Differences in pattern of adherence (MMAS-8) by education and time (“basic” refers to elementary 






























































Abbreviations: COPD–chronic obstructive pulmonary disease; MMAS-8–Morisky Medication 











































4.2. Learnings from the pilot studies 
In each setting, we started an exploratory study with the participation in 6-8 patients. 
The objective of these studies was to get a proof of concept how to go big with the 
project. Finally, I did not manage to scale up the community pharmacy pillar of the 
investigation; the outpatient setting seemed more feasible to reach the desired number 
of patients.  
The scope of these studies were the following: 
(1) what kind of education they would welcome? when and how long are they 
willing to participate? 
(2) what content they would benefit from? 
(3) what is needed so they collaborate for the initial study, as well as during follow-
up? 
For the pharmacy setting, I considered the patient interviews the pilot studies, and finally 
made the decision that due to reduced availability of the patients, I will suspend 
recruitment in this setting. Community pharmacy patients appeared to have more 
inclination towards short interactions and interviews, but they seemed reluctant to take 
part in educational sessions in their free time, especially if they had to come back to the 
pharmacy for the sessions.  
For the outpatient setting, this was performed in district 19 of Budapest. It turned out to 
be a clear benefit for the patients to implement this project while they were waiting for 
the pulmonologist. These exploratory sessions revealed that patients are willing to spend 
20-25 min on questionnaire administration, and more or less, they can concentrate for 
the same amount of time to the education content. Personal meetings were always 
preferred, and the above benefit should be used to ensure their participation. Patients 
were willing to participate voluntarily, and they welcomed more information about their 








4.3. Background of adherence in a wider context 
 The literature search resulted in 188 hits, and five additional records were identified 
through hand search of the references of relevant articles. The screening of the titles and 
abstracts identified 17 potentially eligible studies. After the review of the relevant full 
texts, ten studies were finally included in the systematic review. The flow diagram of the 
systematic literature review process is based on the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) template (89).  
Three studies were randomized controlled trials (RCTs) (177; 178; 179) three 
were prospective cohort studies (180; 181; 182), and four retrospective studies (183; 
184; 185; 186) were also included. The population size varied between 28 and 832 
subjects (185; 186), with a mean age of 9.1 to 28.7 years (177; 185). Seven studies 
focused on measuring adherence to inhaled tobramycin (178; 179; 180; 181; 183; 184; 
186), one on inhaled colistimethate (185), one on inhaled levofloxacin (177), and one 
on inhaled aztreonam lysine (182). The general characteristics of the reviewed studies are 
summarized in Table 12. 
Medication adherence to inhaled ABs was analyzed by pharmacy refill history (30%) 
(183; 184; 186), daily phone diary 10%) (181), parent and/or child self-reports (20%) 
(180; 181), vials counting (30%) (177; 178; 182), or electronic monitoring (10%) 
(185). 
(179) did not describe the method for measuring adherence, while (181; 182) did not 
report how adherence was defined in their studies. Six studies (177; 179; 178; 180) 
determined adherence as categorical variable only, four studies (181; 182; 184; 185) as 
continuous only, and one study as both (179). Measurement methods, results, and 
predictors/consequences of adherence to inhaled ABs are presented in Table 12. 
Except for the studies conducted by (184; 181) most studies assessed adherence to 
inhaled ABs only and did not evaluate adherence to other medications simultaneously 
(Table 13). 
The included studies fulfilled the STROBE criteria between 52% (185) and 73% 
(179; 186). The majority of the studies described their scope, study design, settings, 







of the reviewed studies described their statistical methods in detail; however, none of 
them undertook a sensitivity analysis to examine the robustness of the results. 
Furthermore, no study provided information on missing data and how they dealt with the 
same. 
Table 12: Summarized adherence data from randomized control trials and real world studies  









Table 13: Overview of retrospective trials  












5.1.Attitudes and perception of pulmonologists and patients 
High awareness levels are needed for the programme to be successful (172; 57), so we 
ensured this continuous contact by providing a leaflet that summarizes education 
content, and patients can recap on it whenever they wish.  
By recognizing the information level they already had (90), we provided an opportunity 
to ask questions they were interested in. This was implemented only after the education 
sessions, in order to avoid that education sessions are not formalized and ubiquitous, 
which is the pre-requisite to make the sessions intercomparable.  
In the long run, we have to trigger a change in the patient’s life (44; 167), and that the 
patient is willing to intervene in his or her daily rhythm that is better enables disease 
management (167). Ideally, this is done in an integrated approach, meaning that the lung 
therapist is primarily involved in patient care, and secondly the GP and pharmacist are 
involved in the care (164). In our setting, we initiated this lifestyle changes by 
incorporating breathing techniques in the education sessions; and integrated care was 
investigated by the incorporation of the two key actors in COPD care in Hungary: the 
pulmonologist and the pharmacist. 
In terms of adherence, our data are consistent consistent international literature, 
particularly in terms of combination therapy (values of inadequate adherence vary 
between 50-70% (169). The high standard deviation is also characteristic of the 
summary studies (1), and the similar study from Hungary (24) shows the number of 
COPDs with optimal adherence are at around 60%, this is a much more positive value 
than what is outlined in the interviews. Higher adherence can be expected under 
supervision and in clinical trials (1), so education is expected to positively influence on 








5.2.Impact of education on quality of life and adherence  
In this first of its kind study to determine the effect of patient education on treatment 
adherence and QoL in subjects with COPD in Hungary, we noticed a clear association 
in between patient education and adherence at the time of follow up. In the parameters 
tested using the MMAS-8 scale, there were statistically significant changes in total score 
and for M4 and positive trends in M2, and M7 (Table 10). This implies that adherence 
improved in relation to: 
(1) taking medication in the two weeks preceding the follow-up visit,  
(2) remembering to take medications when travelling or leaving home, and  
(3) being more comfortable with the treatments.  
Furthermore, a substantial proportion of our subjects reported either good (41.5%) or 
moderate (43.2%) adherence by the end of the study.  
It should be noted that this study captures the data related to slightly more women than 
men. Event though pulmonologists identified men among the basic characteristics of the 
COPD patient, our target population included ca. 10% more women than men. This 
implies that women might be more disease conscious, or may take follow-up visits more 
seriously (since every tenth patient was offered the opportunity to take part in this study, 
men and women should have been represented in the same proportion in line with the 
natural gender distribution).  
In comparison with another study from our research group (187), baseline SGRQ quality 
of life status seems to be higher (scores are lower, but this indicates and inverse 
relationship with quality of life status). This implies that our subjects could have 
reported been in better health status; consequently, demonstrating an improvement on 
the already higher values might be less likely than in the case of starting from quality of 
life status. Altogether, our sample includes more women and subjects with lower SGRQ 
scores, which means that our results might be more focused on women with better 
disease specific life.  
The assumption that patient education would result in improvement of patients’ QoL 
has been well supported by numerous studies (19; 20; 26), including in a hospital setting 







statistically valid, we were able to discern noticeable trends in certain aspects of the QoL 
algorithms. Two of these were the CAT2 and CAT8 scores (Table 10) which imply that 
patient education improved subject perception of the amount of mucus in their 
respiratory system. With these algorithms, we also noted that our subjects reported 
feeling less energetic at follow-up although we speculate that this could be due to a 
change in patient attitudes for the lengthy follow-up procedure. We also observed 
certain gender-specific trends: our male subjects tended to show an improvement in 
CAT3 and CAT6-8 scores indicating that they felt less chest pain, were more confident 
when leaving their homes, were sleeping better, and felt more energetic due to the 
educational intervention. On the other hand, the changes in CAT6 scores in our female 
subjects suggest that they were more symptom-conscious at the time of follow-up. These 
findings suggest that perhaps patient education programs will have to be tailored by 
gender as well as the individual in order for patients to successfully manage their COPD. 
We must also note here that while we designed our education content in order to keep it 
simple and provide key messages to our subjects. Furthermore, in the interest of 
consistency, we provided the same content to all study subjects without any 
personalization or alteration.  
Medication adherence has been shown to be associated with certain sociodemographic 
characteristics such as gender, age, affluence, and education (188). Higher education 
levels in patients are associated with better health literacy and medication knowledge 
(189; 190; 191). Consequently, these patients could be more proactive about seeking 
medical attention, adherent to prescribed treatments, and seek to make appropriate 
lifestyle changes. In our study, we noticed that subjects who had a university-level 
education scored better on question M8 on the MMAS-8 scale, which asked subjects if 
they had trouble remembering to take their medication.  However, this finding also 
indicates that other appropriate measures will have to be developed to help improve 
adherence in patients who are not as educated. 
One of the goals of our study was to identify any three-way correlation between patient 
education, adherence, and QoL. However, we could not discover any statistically valid 
correlation between adherence and QoL. Despite this, we did notice a loose association 







symptoms, as measured by CAT, correlate to decrease in QoL scores, as measured by 
SGRQ. In other words, the more symptoms a patient perceives, the worse they score on 
the QoL scale, especially on issues related to daily activities and societal impact. 
Additionally, the changes in SGRQ were paralleled by changes in the EQ-5D scores 
indicating that these trends move in the same direction. Larger studies will be required 
in the future in order to ascertain whether such patterns are a true effect or an aberration.  
While our study provides a few insights on association between patient education and 
management of COPD in the outpatient scenario in Hungary, it was limited in scope. 
Since our study was a longitudinal cohort investigation, we did not have a control group, 
ie, subjects who received no professional counselling. While our sample size was 
adequate for our main objective, the results from our sub-group analysis cannot be 
reliably extrapolated to the general population with COPD. Furthermore, we did not 
classify our subjects according to the Global Initiative for Chronic Obstructive Lung 
Disease guidelines, which would have helped us; better understand their status, 
symptoms, and risk of exacerbation. Lastly, we did not analyze the data from our 
subjects for the effect of seasonal fluctuations, which are known to have an impact on 
severity of COPD symptoms. 
It should be noted that our study focusses on hard endpoints and joins the mainstream 
direction of outcome based research. This certainly implies that intermediate effects of 
education was less measured than the value it captures at the level of therapy experience 
and adherence patterns. In order to assess the ad interim results of patient eduation, 
patient satisfaction or knowledge are assessed. In this study, we applied a single-item 
question to measure the impact of education on treatment regimens. The seventh 
question of MMAS-8 measures if patients are more able to adhere to daily treatment 
regimens, where endline scores show a positive trend (almost significant) in comparison 
with baseline scores. This implies that the education session positively influenced 
medication taking, and provides an intermediary link between education and the hard 
endpoint (patient reported outcome).  
To provide a more holistic frame to our research, the factors potentially affecting the 
quality of life and adherence besides the education we provided, should be discussed. 







interpreted at the patient level: physical characteristics of the patient (age, weight, 
fitness), comorbidity (cardiological, psychiatric, asthma overlap), characteristics of 
therapy (fast effect, cheap effect), and psychic status. 
The most widely used disease-specific quality of life questionnaire in COPD, SGRQ 
distinguishes three dimensions: symptoms (part 1), activities, and effects (part 2). 
Accordingly, these three main effects should be interpreted as the leading determinants 
of disease that affect quality of life.  
Adherence is also multifactorial, here we suggest the following summarizing categories: 
(1) Personality of the patient (age, personality traits, education, beliefs, relationship 
to alternative therapies, psychological status); 
(2) Characteristics of the disease (severity, presence, progression, lifestyle impact, 
disease awareness, comorbidities); 
(3) Characteristics of the therapy (mode of administration, frequency, duration and 
cost, side effects, previous therapies, fast onset, ergonomic considerations for 
the drug, success); 
(4) Doctor-patient relationship (personality, intimate atmosphere, professionalism, 
concentration, “rituals”, messages); 
(5) Features of the healthcare system (environment, waiting time, helpfulness of 
support staff, pharmacy availability, often changing prices or prescribing rules). 
While designing the study, we sought to exclude other factors that influence patient 
quality of life. Consequently, patients with exacerbation within 3 months, other lung 
diseases, severe and uncontrolled cardiac disease, and uncontrolled mental problems 
were excluded, when designing the inclusion criteria. The 3-month control was defined 
as patients whose natural history did not require a change of medication, so external 
factors were considered unchanged except for education (including demographics). The 
internal consistency of the education was ensured by training the trainers, randomly 
checking them, and providing patient content with a fixed content for the formalized 
part of the education. Finally, this implies that the changes in the scores are attributable 







To put our research in a further context, it should be considered what broader outcome 
measures exist (134). In this research, PROs were preferred as the most patient centric 
quantifier. 
(1) Patient reported outcome: outputs that represent value to the patient in any forms 
(physical fitness, asymptomatic, quality of life parameters). For the sake of 
comparability, we use a validated questionnaire to ensure comparability with 
international research trends and results across sites. 
(2) Clinical outcome: the patient’s objective clinical parameters should be the 
primary consideration; this is lung function, especially the FEV1. Previous 
clinical practice has examined this as a primary result, but insight that is more 
contemporary considers patient reported outcomes (too).  
(3) Social and economic outcomes: at the societal level, we can broadly interpret the 
importance of education, as the positive impact on adherence reduces the social 
burden of the disease and reduces patients’ sick leave. At the (health) economics 
level, the effectiveness of education can be interpreted as the QALY gain if there 








5.3. Background of adherence in a wider context 
Ten studies were identified and included in this systematic review (177; 178; 179; 180; 
181; 183; 184; 185; 186; 182). The majority of the studies focused on measuring 
adherence to inhaled tobramycin (n=7) (178; 179; 180; 181; 182; 183; 186). To our 
knowledge, this is the first systematic review of the adherence to inhaled ABs in CF. The 
results from the present study contribute to understanding the current status of 
adherence to inhaled ABs and for planning future research that can add to the global 
picture of adherence in CF. 
5.3.1. Methodological issues: RCTs vs real-world studies 
Most of the included publications were real-world studies (n=7) (180; 181; 182; 183; 
184; 185; 186) contrary to RCTs (n=3) (177; 178; 179). From the viewpoint of health 
care professionals, real-world studies provide more reliable information about medication 
adherence in contrast with RCTs, which may overestimate adherence. As RCTs are 
mainly designed to assess safety and efficacy of pharmaceuticals, the study design 
emphasizes internal validity over generalizability. In these studies, because of protocol 
requirements, the data may not be applicable to the more heterogeneous patient group 
encountered in actual clinical practice. Effectiveness studies (eg, prospective cohort 
studies and retrospective studies), where treatment and/or disease management is 
studied under real-world conditions (eg, in unselected populations; patients are under 
routine care, taking open-label treatment, with no additional visits), remedy some of 
these limitations. This issue is especially relevant in case of adherence data. In RCTs, 
usually better treatment adherence is obtained due to the continuous, obligatory control 
visits or measurement of serum drug levels. Moreover, patients sometimes feel that 
they are in favored situation, because they are eligible to take part in the study and use 
a novel, not launched medication in CF. In addition, between regular visits, phone calls 
also remind patients to the use/ administration of the drug, or they are asked about 
their experiences related to the new drug. 
In the included RCTs (177; 178; 179), the proportion of adherent patients (75%-
80% of required doses taken) ranged between 86.4% (inhaled tobramycin, 







measured by vials counting) (177). In contrast, in the prospective cohort study (180) 
only 44.9% of patients reported greater than 80% adherence to TIS (tobramycin 
inhalation solution) and 7.5% to tobramycin inhalation powder (TIP) (measured by 
patient self-report). In the included retrospective studies, the proportion of highly 
adherent patients (4 fills per 12 months) was found to be in the range of 7% (inhaled 
tobramycin, measured by pharmacy refill records) (183) to 29.6% (inhaled tobramycin, 
measured by pharmacy refill records) (186) (Table 12). 
5.3.2. Adherence rates to inhaled antibiotics 
Determining an overall rate for adherence to inhaled ABs in CF was difficult because 
different adherence definitions and measurement methods were applied in the 
reviewed studies; furthermore, two of the included studies (181; 182) did not declare 
a clear definition for adherence. In prospective cohort studies, adherence rates ranged 
between 36% (inhaled tobramycin, measured by daily phone diary), and 92% (inhaled 
aztreonam, measured by vials counting) (182), and in retrospective studies it ranged 
between 60% and 70% (inhaled colistimethate, measured by electronic monitoring) (185) 
(Table 12). Adherence to inhaled ABs did not differ significantly from adherence rates 
to other CF-related medications (Table 13) (184). 
5.3.3. Predictors of adherence 
In the reviewed studies, adherence to inhaled ABs was found to be associated with 
the age of patients, patient’s satisfaction, treatment burden (ie, adverse events and taste), 
and time of drug administration (ie, morning vs evening inhalation) (179; 183; 185). 
Treatment adherence was better in those patients who were younger than 12 years of 
age (12 years of age: 71% vs $12 years of age: 50%) (185). A reasonable explanation 
may be the presence of parental supervision in this age group. This result is similar to 
the findings (181), who reported that parental supervision of CF medical treatments can 
improve children’s treatment adherence. Furthermore, preadolescents and adolescents 
who spent more of their treatment time supervised by mothers had better adherence. 
Interestingly, (184) could not identify any relationships between age and treatment 
adherence. Patient satisfaction with inhalation AB therapy was linked to patient 







their inhaled ABs in CF (179). Patients’ self-perception about the efficacy of the drug 
(192), clinical response (192), cumulative toxicity (192), drug intolerance (183), 
treatment burden, and the time and frequency of administration24 could determine 
adherence to therapy. Evening adherence (75%) was significantly better than morning 
adherence (58%) to inhaled colistimethate (185). A possible explanation of this 
phenomenon could be that children have to wake up early in the morning for complete 
airway clearance, chest physiotherapy, and inhalation before going to school. Unpleasant 
taste of the inhaled AB, delay in the improvement of lung function (FEV1), and respiratory 
symptoms may also lead to non-adherence (177; 183; 193). Furthermore, adherence to a 
novel medication may be better than to an older one (177). 
Real-world studies enable better understanding of the predictors of non-adherence from 
patients’ viewpoint compared with RCTs. However, since measuring adherence to 
inhaled ABs as a phenomenon is relatively new, many of its potential predictors have 
not yet been evaluated, such as relationship between treatment adherence and health-
related quality of life, relationship between clinical parameters (eg, FEV1) and 
adherence, or direct comparison of adherence between various type of inhaled ABs in 
CF. 
5.3.4. Consequences of non-adherence 
In RCTs, high adherence was observed between artificial conditions compared to real-
world studies. Therefore, this analysis made conclusions about consequences of non-
adherence on the basis of results published by real-world studies (180; 181; 182; 183; 
184; 185; 186). Most studies concentrated on the level of adherence, on the 
identification of non-adherence, and on how adherence can be improved. However, only 
few (n=4) researches dealt with the consequences (180; 183; 184; 186). Further studies 
are needed to understand the clinical consequences of non-adherence in CF. 
Generally, the examination of financial impact, not the clinical impact, of poor 
adherence dominated in the reviewed articles. However, it was difficult to clarify the real 
effect of non-adherence on clinical outcomes because of the natural progression of the 
disease. There are many factors (eg, microbiological agents and CF-related 







progression of the disease. Our analysis suggests that better adherence to inhaled ABs 
in patients with CF is significantly associated with decreased health care utilization, 
median outpatient costs, excluding drug costs, and decreased risk of hospitalization 
(183; 186). Moreover, reductions in CF-related hospitalizations translated to 
significant reductions in CF-related inpatient costs. That could mean that low-
adherence users may have more frequent pulmonary exacerbations and CF-related 
complications (186). However, that adherence to inhaled tobramycin was not 
significantly associated with the occurrence of pulmonary exacerbation and change in 
FEV1% predicted slope (184). 
5.3.5. Enhancing adherence 
Only few of the authors of the reviewed articles developed suggestions on how 
adherence to inhaled ABs can be improved. Changing treatment regimen from twice 
daily to once daily significantly improved adherence (26% vs 54%, in 1 month) (185). 
In a real-world, prospective cohort study, the use of a more rapid delivery system 
could result in increased adherence to inhaled ABs (180). In their research, TIP was 
associated with better adherence compared with TIS (Table 12). 
In the recent years, some useful tools have been developed to improve medication 
adherence in patients with CF. Internet-based adherence interventions and mobile 
phone applications became more and more popular (194). Besides telemedical 
patient management, it still seems important to improve patient education programs to 
provide home service programs in collaboration with social workers. However, the 
most important issue is to recognize the necessity of routine adherence monitoring 
during CF care. It is also important that physicians do not expect adherence to be the 
sole responsibility of patients, because improving treatment adherence is teamwork. 
Clinicians should understand their patients’ problems in relation to side effects or with 
time of administration and help patients to choose an inhaled AB that is the best for 
the patient. If adherence is routinely monitored and results are discussed openly with 
patients, then treatment regimens can be individualized for patients. This kind of 








5.4.Research objectives & hypotheses 
The following research objectives and hypotheses were set for this research, and I can 
provide the following argumentation to discuss their accomplishment:  
Objectives 
(1) to assess the attitudes of two key players (patient, physician) in COPD patient care. 
This new methodology should be reproducible, widely applicable, and personalized 
& understandable to patients.  
Patient and pulmonologist intervews were conducted, and they provided input to 
the education content that I have applied in three study centers (see Chapter 4.1). 
Patient knowledge on treatment regimens was evaluated, and the education has 
positively affected this parameters, whilst I demonstrated significant improvement 
of total adherence scores.   
For the pulmonologist interviews, I set the following project specific objectives: 
4.3.1.1. to develop a patient education program that is based on the expert 
opinion of pulmonology therapists who play a key role in the care of COPD 
patients; 
The patient education program was successfully designed, implemented and 
reported, please see Chapter 4.2 that describes the impact the project created.  
4.3.1.2.  to understand the perceptions and attitudes of the pulmonary therapist, 
and to gain a comprehensive landscape of patient and condition, the success of 
the treatment, and their relation to adherence; 
The COPD patient profile, therapeutic attitudes of pulmonary therapists were 
reported in Chapters 4.1 and discussed in 5.1. 
4.3.1.3.  to assess the potential of improving patient adherence in outpatient care, 
rehabilitation and hospital settings. 
The adherence aspects of patient education are highlighted in the results section 
(4.1), and due to the patient population of the pulmonologist interviews, I have 
incorporated knowledge of specialists of all three affiliations mentioned above. 







4.3.1.4. to assess the opportunities of COPD disease management in the 
community pharmacy setting; 
Although our results highlight that the pharmacy setting is not an ideal place for 
education for our study, our pilot study conducted in the Inczeffy Pharmacy 
provided an insight to patient attitudes by in-depth interviews.  
4.3.1.5. to understand patient attitudes, perceptions, fears, beliefs that affect the 
everyday life of patients; 
Results of patient data are available in Chapter 4.1.2. This knowledge was used to 
compile a guide to the education content patients would welcome (see Chapter 6.1). 
4.3.1.6. to create a local good practice and to investigate how the community 
pharmacy pillar of integrated care can work in the context of Hungary.  
Integrated care is defined in this thesis as the collaboration between the GP, 
pharmacist and the medical specialist. The community pharmacy and the outpatient 
center opportunities have been explored, though it was implemented in different 
localities (district 13, 19 of Budapest, Vác and Göd for the pharmacy). We have 
created a local good practice in the city of Göd for the benefit of patients, which 
can be complemented in the future by further integration of pulmonologists from 
the same region and GPs.  
(2) to conduct pilot studies to determine the optimal scenario to go live with the 
education project; 
Pilot studies were implemented both in the pharmacy and in the outpatient center (the 
latter one was not sufficiently moderated to report systematically) with the participation 
of 6-20 in each location. The education project went live as assumed.  
(3) to investigate the effect of education on quality of life and adherence of COPD 
patients at different study sites (Budapest and the countryside) by a different set of 
validated scales; and to investigate the longitudinal effects of education; 
Validated scales were selected as described in Chapter 1.4, the study site scope was 
accomplished, and the longitudinal feature was assured by a 3-month follow-up. The 







(4) to propose the ideal conditions of education (pharmacist care in the community 
pharmacy setting or pulmonologist care in the outpatient setting with nurses); 
For this study, the pharmacy setting was excluded from follow-up due to the limited 
number of patients. Also, we had to consider the patients’ desire to be primarily 
education in the pulmonology outpatient center, especially when they are waiting for 
examinations. Consequently, we have chosen the outpatient center setting to recruit the 
bulk of our participants.  
(5) to understand the background of adherence in a wider context of pulmonary 
conditions, including the different setting of cystic fibrosis. 
The review that our research group has published was written upon the request of the 
journal, which demonstrates the need from the scientific community for such a journal 
article. The detailed discussion section in Chapter 5.3 provides this wider context to 
inhalative therapy in CF. 
Hypotheses 
(1) Patient-centered education content can be developed based on the attitudes and 
perceptions of pulmonologists and patients.  
I accept the first hypothesis, because my PhD research successfully developed this 
education content.  
(2) This education content has a positive impact on medication adherence and quality 
of life, and this demonstrated by validated scales.  
Total medication adherence scores and certain dimensions were proven to be 
significantly better due to education, whilst a positive tendency was demonstrated 
on certain elements of COPD symptomatology. I accept this hypothesis, since 
certain elements improved, though not all of them improved. 
(3) A methodological overview to broaden the scope with CF medication adherence 
will help me reveal more about adherence patterns and patient attitudes in 
respiratory conditions. 
I accept this hypothesis, since the appraisal is ready and it provides the desired 








6.1.Attitudes and perceptions 
The perception project has managed to meet the objectives that were observed 
previously. Conclusions to prepare the educational content, based on pulmonologist 
expert opinion, will be summarized in the following points and by Figure 18A: 
(1) As for patient profile, pulmonologists generally meet male patients who are under 
socialized, breathless, coughing, smoking. If a patient brochure is created, it is 
recommended that we use such a sample patient so that they feel more attached to 
the material. Further implications include plain language, especially by including 
the words they use.  
(2) Patients should be educated from the basics, since currently awareness and disease 
acceptance are missing. Consequently, it is necessary to explain the acronym 
COPD, laying stress on the chronic component of the disease (eg. medication 
cannot be stopped if symptoms are ameliorated); to make sure about the 
relationship between smoking and COPD, and to promote smoking cessation.  
(3) The unambiguous symptoms of the disease, such are fatigue, coughing and 
breathlessness should be associated with it, and the education sessions should 
explain how the treatment resolves these symptoms (consistent with the lack of 
disease coverage). Patients should understand what is the role of each medication 
(at least if it is a reliever or maintenance therapy), and the supremacy of long-term 
treatment over the frequent administration of the fast onset relievers. 
(4) Correct dosage, frequency, and proper inhaler use should be the part of everyday 
life. It should be clear that the lack of adherence is associated with more frequent 
GP visits and exacerbations, and the latter vastly deteriorates quality of life and 
long-term survival rates. Consequently, the patients has to know when to contact 
the doctor and when not to. 
(5) Bidirectional and open communication between patient and healthcare provider, 
and the question of trust have also appeared in the interviews, which elevate this 
process to a higher level. Patient engagement and self-management are fostered if 
the above are created and the patient is willing to take responsibility of their 








Figure 18A: Patient education content based on pulmonologist opinion 
According to interviews, COPD patient education is badly needed. It is useful to do this 
in a structured way, using the experience of specialists, according to the patient's 
language and level of knowledge (195). Above we have presented attitudes regarding 
the diagnosis of COPD, the physician's patient picture, the patient's adherence, and the 
inhaler. 
It would be interesting to further develop research: a higher number of subjects, 
conducting similar studies among patients, and extending the scope to the overlapping 
issues of quality of life and quality of life and adherence. 
In conclusion, patient education is of paramount importance in the treatment of COPD. 
Considering the lessons of this article, it is worth developing a training program tailored 
to the local context that addresses the needs of stakeholders (196). 
Patient interviews vastly reveal the missing concepts, lack of pragmatic knowledge and 
(non)-adherence data that should be tackled by in our education program. A patient 
education project was piloted in the community setting, and we will do our best to ensure 
the scientific support to its continuation (hopefully this means this initiative will 
continue on the long-term in Göd). Furthermore, this study has the benefit to envision 
the three key intervention areas that should be targeted by an education program. 
(1) A relatively small number of COPD patients prefers the pharmacy to get 
education; however, those who come indeed, are motivated.  
• What does COPD stand for? What does "chronic mean"?
• What happens to my lungs vs. the healthy ones?
• Signs and symtoms
Pathophysiology & COPD
• What elements does my treatment have?
• How to use correctly my inhaler?
• Reliever and maintenance therapy
Treatment
• What consequences does smoking have?
• Breathing techniques and posture








(2) Patients get used to COPD, and they accept “that this comes by age”, “I cannot 
do this”, though all of them mentioned an activity they still wish to pursue.  
(3) Active listening to patient needs is an effective way to reveal important insight 
(146). Namely, asking semi-structured questions; and permitting them to talk 
about their issues helped us create the guidelines for such content they can 
benefit. Recording patients’ words and phrases also helps us to put together an 
easy-to-understand material with catchy content. 
(4) There is a need to expand the project, since once the patients decided to open up, 
they share all their experience; furthermore, these patient clubs are also in favor 
of their social inclusion and provide an opportunity to meet their peers.  
(5) Figure 18B seeks to incorporate the patient insight to an ideal education content. 
Since the project was well accepted, a local epitome has been created in the 
Inczeffy Pharmacy.  
 
Figure 18B. Elements of the suggested education content by COPD patient interviews 
It is worth comparing Figure 18A and 18B. Even though patients and pulmonologists 
communicate differently about COPD, the major elements turned out to be similar. All 
mentioned topics were grouped in three, and three major areas of interest could be 
identified. Education content was finally developed using these results, and internal bias 
was diminished by applying two independent evaluators for patient and pulmonologist 
interviews.   
• COPD knowledge, meaning and treatment of exacerbations
• Differentiation from asthma and reinforcing disease 
acceptance & awareness
• Symptoms and their management
Disease knowledge
• Identification of medications, dosage (if available, SMART)
• Inhaler use & ancillary actions
• Maintenance therapy and reliever use with maximal daily use
On the way of improved 
adherence
• Engagement to the education project
• Connection to smoking & helping to stop it








6.2.Impact of education on quality of life and adherence  
In conclusion, although we did not establish a clear relationship between patient 
education and QoL, we were successful in demonstrating an association in between 
patient education and medication adherence. Our research highlights the groups that are 
receptive to education and parameters that affect adherence in the environment of an 
outpatient pulmonology center, where the context is fixed, internal consistency of the 
education ensured, and patients continue with their medications for a period of three 
months. Patient education results in an improvement in adherence, especially in unique 
situations such as being away from home. Larger studies will be required to assess the 
adequacy of current patient counselling strategies and implement newer and improved 








6.3.Background of adherence in a wider context 
Different adherence definitions and measurement methods made it difficult to 
determine an overall rate for adherence to inhaled ABs in CF based upon the reviewed 
studies. Our analysis suggests that probably because of their highly controlled 
conditions, RCTs provide higher adherence rate to inhaled ABs than real-world 
studies. Adherence to inhaled ABs was found to be associated with the complexity of 
treatment, time of drug administration, age of patients, treatment burden (ie, adverse 
events and taste), and patient satisfaction. Further research is needed to better 
understand the predictors of adherence to inhaled ABs, which would be critically 
important to the development of effective adherence-enhancing interventions. Routine 
adherence monitoring, discussing the possible reasons of non-adherence with the patient, 
and changing treatment regimens on the basis of patient burden may optimize patient 








6.4. Novelties  
This body of research had the objective to contribute to our existing knowledge of 
COPD patient education, quality of life and adherene, and CF adherence in the 
Hungarian context. This PhD thesis has managed to demonstrate the following 
novelties: 
(1) It has envisioned The Hungarian COPD patient profile by pulmonology in-depth 
interviews; 
(2) It has described the perceptions and attitudes of Hungarian pulmonologist related 
to COPD treatment and adherence; 
(3) It has created a patient centered education content that is tailor-made to the needs 
of Hungarian patients; 
(4) It has created the major guidelines, along which pulmonologists think that COPD 
patients can be educated (this provided a fix element to the education project); 
(5) It has initiated a local good practice in the Inczeffy Pharmacy in Göd with a pilot 
community pharmacy project to gather patient insight and information of the 
implementation of such an educational project in the pharmacy setting; 
(6) It has described attitudes and perceptions related of Hungarian COPD patients 
related to COPD treatment and adherence; 
(7) It has performed impact studies in Hungary as a pioneer to demonstrate the impact 
of COPD patient education of a diverse set of quality of life and adherence 
questionnaires; 
(8) It has demonstrated significant correlation with total adherence and positive or 
significant correlation with dimensions of adherence (especially in unique 
situations such as being away from home, being more treatment-conscious and 
taking medication at 2 weeks after the medical visit); 
(9) It has provided a peer reviewed overview of challenges of CF treatment, along with 








The PhD thesis have met three pre-study objectives; additionally, the advances to our 
current knowledge are highlighted.  
Firstly, it had the objective to develop a patient-centered education content with the 
inclusion of pulmonologist expert opinion and patient needs for the first time in 
Hungary. 
Secondly, it had the objective to measure the impact of this education program on the 
adherence quality of life of COPD patients, also considering the long-term benefits, 
pioneering with a complex set of dimensions with Hungarian patient data. 
Thirdly, it had the objective to gather insight into adherence patterns in a wider range in 
pulmonology, by including cystic fibrosis as a model disease.  
The study has shown that pulmonologist and patient attitudes are different, especially 
articulated differently. However, when they are summarized by two independent 
evaluators, needs can be unified by a tailor-made patient education program, which was 
structured for the study to ensure inter-comparability.  
The structured education was performed n=118 times, and the same number of patients 
benefited of the long-term benefits. We used a various range of adherence and quality 
of life scales, which had been carefully selected for the target population, taking 
availability, cost-effectiveness and target willingness into account. Adherence was 
measured on the latest and most complete MMAS-8 scale; whilst symptomatology was 
measured by the standardized CAT test; disease-specific quality of life was measured 
by the SGRQ test, and general quality of life on the EQ-5D-5L and VAS scales.  
Our results highlight that this educational program was successful, marked effects were 
registered especially related to adherence. Statistically significant improvement was 
achieved on the overall adherence scores, which are supported by the following 
dimensions: “pre-visit medication taking”, “taking medication when leaving home” and 
“overall comfortability with the treatment”. Our methodological overview summarizes 
the main factors determining adherence in CF, which helps this thesis broaden its 








A doktori értekezés három előre meghatározott célt teljesített; valamint az alábbiak 
összefoglalják a munka tudományos értékét.  
Először, egy betegközpontú oktatási program kidolgozását tűzte ki célul, a 
pulmonológus szakértői véleményének és a betegek szükségleteinek bevonásával 
elsőként Magyarországon. 
Másodszor, a célom az volt, hogy ennek az oktatási programnak a COPD-s betegek 
életminőségére és adherenciájára gyakorolt kvalitatív és kvantitatív hatását leírjam, 
figyelembe véve a hosszú távú előnyöket és az egyes dimenziókat is. 
Harmadszor, a célom az volt, hogy az adherencia kérdéseit szélesebb kontextusban, a 
cisztás fibrózist mint modellbetegséget is bevonva vizsgáljam.  
A tanulmány kimutatta, hogy a pulmonológusok és a betegek attitűdje eltér, 
különösképpen másképp kommunikálnak ezekről. Két független értékelő bevonásával 
mindkét kulcsszereplő szempontjait figyelembe véve egy betegérdekekre szabott 
oktatóprogramot fejlesztettem ki (ezt a vizsgálat során fixesítettük, hogy a mérések 
összehasonlíthatóak legyenek). 
Oktatásban n = 118 beteg részesült, őket longitudinális vizsgálatban 3 hónapos 
utánkövetéssel vizsgáltuk. Az adherenciát az MMAS-8 skálán mértük; míg a tüneteket 
a CAT-teszttel; a betegség-specifikus életminőséget az aranystandard SGRQ-teszttel, az 
általános életminőséget az EQ-5D-5L és a VAS-skálákon mértük.  
Az eredmények rámutattak arra, hogy ez az oktatási program sikeres volt, különösen az 
adherencia tekintetében. Statisztikailag szignifikáns javulást írtam le a teljes adherencia-
pontszámot illetően, valamint egyértelmű javulást az alábbi dimenziókban: „vizit előtti 
gyógyszeres kezelés”, „gyógyszer szedése otthonról távozáskor” és „általános 
kezeléssel való elégedettség”.  
Módszertani áttekintésünk összefoglalja azokat a fő tényezőket, amelyek leírják a 
cisztás fibrózisban alkalmazott inhalatív terápiával kapcsolatos adherencia 
megfontolásait, ezáltal kitekintést adnak más, hasonló tüdőgyógyászati kórképben leírt 








1. López-Campos JL, Tan W, Soriano JB (2016). Global burden of COPD. Respirology, 
21: 14-23.  
2. Raherison C, Girodet P-O (2009). Epidemiology of COPD. European Respiratory 
Review. 18: 213-221. 
3. de Marco R, Accordini S, Marcon A, Cerveri I, Antó JM, Gislason T, Heinrich J, 
Janson C, Jarvis D, Kuenzli N, Leynaert B, Sunyer J, Svanes C, Wjst M, Burney P and 
(2011), (ECRHS). Risk factors for chronic obstructive pulmonary disease in a European 
cohort of young adults. Am J Respir Crit Care Med. 183: 891-897.  
4. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM (2006). 
Systematic review and meta-analysis.  Eur Respir J. 28: 523-532.  
5. Ejiofor S, Turner AM (2013). Pharmacotherapies for COPD. Clin Med Insights Circ 
Respir Pulm Med. 7: 17-34.  
6. Newman SP (2005). Inhaler treatment options in COPD.  Eur Respir Rev. 14: 102-
108.  
7. Vestbo J1, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, Knobil K, 
Willits LR, Yates JC, Jones PW (2009). Adherence to inhaled therapy, mortality and 
hospital admission in COPD. Thorax. 64: 939-943.  
8. Mäkelä MJ, Backer V, Hedegaard M, Larsson K (2013). Adherence to inhaled 
therapies, health outcomes and costs in patients with asthma and COPD.  Respir Med. 
107: 1481-1490.  
9. Mitchell SE, Sadikova E, Jack BW, Paasche-Orlow MK (2012). Health literacy and 
30-day postdischarge hospital utilization.  J Health Commun. 17: 325-338.  
10. Barlow J, Wright C, Sheasby J, Turner A, Hainsworth J (2002). Self-management 
approaches for people with chronic condition: a review.  Patient Educ Couns. 48: 177-
187.  
11. Hammond A, Bryan J, Hardy A (2008). Effects of a modular behavioural arthritis 
education programme: a pragmatic parallel-group randomized controlled trial.  
Rheumatology (Oxford). 47: 1712-1718.  
12. Jordan JE, Osborne RH (2007). Chronic disease self-management education 
programs: challenges ahead.  Med J Aust. 186: 103-104.  
13. Bodenheimer T, Lorig K, Holman H, Grumbach K (2002). Patient self-management 







14. Lorig KR, Ritter P, Stewart AL, Sobel DS, Brown BW Jr, Bandura A, Gonzalez 
VM, Laurent DD, Holman HR (2001). Chronic disease self-management program: 2-
year health status and healthcare utilization outcomes.  Med Car. 39: 1217-1223.  
15. Folch-Ayora A, Orts-Cortés MI, Macia-Soler L, Andreu-Guillamon MV, Moncho J 
(2019). Patient education during hospital admission due to exacerbation of chronic 
obstructive pulmonary disease: Effects on quality of life – controlled and randomized 
experimental study. Patient Educ Couns. 102: 511-519.  
16. Howcraft M, Walters EH, Wood-Baker R, Walters JA (2016). Action plans with 
brief patient education for exacerbations in chronic obstructive pulmonary disease. 
Cochrane Database Syst Rev. 12: CD005074.  
17. Wang L, Mårtensson J, Zhao Y, Nygårdh A (2018). Experiences of a health coaching 
self-management program in patients with COPD: a qualitative content analysis. Int J 
Chron Obstruct Pulmon Dis. 13: 1527-1536.  
18. Abdulsalim S, Unnikrishnan MK, Manu MK, Alrasheedy AA, Godman B, Morisky 
DE (2018). Structured pharmacist-led intervention programme to improve medication 
adherence in COPD patients: A randomized controlled study. Res Social Adm Pharm. 
14: 909-914.  
19. Ruud KW, Rønningen SW, Faksvåg PK, Ariansen H, Hovland R. E (2018). 
Evaluation of a structured pharmacist-led inhalation technique assessment service for 
patients with asthma and COPD in Norwegian pharmacies. Patient Educ Couns. 101: 
1828-1837.  
20. Blackstock FC, Lareau SC, Nici L, ZuWallack R, Bourbeau J, Buckley M, Durning 
SJ, Effing TW, Egbert E, Goldstein RS, Kelly W, Lee A, Meek PM, Singh S and ATS, 
TSANZ, CTS, BTS (2018). Chronic Obstructive Pulmonary Disease Education in 
Pulmonary Rehabilitation. Ann Am Thorac Soc. 15: 769-784.  
21. Vincent EE, Chaplin EJ, Williams JE, Harvey-Dunstan T, Greening NJ, Steiner MC, 
Morgan MD, Singh SJ (2017). Experiences of patients undergoing pulmonary 
rehabilitation during an exacerbation of chronic respiratory disease. Chron Respir Dis. 
14: 298-308.  
22. Kokturk N, Polatli M, Oguzulgen IK, Saleemi S, Ghobain MA, Khan J, Doble A, 
Tariq L, Aziz F, Hasnaoui AE (2018). Adherence to COPD treatment in Turkey and 
Saudi Arabia: results of the ADCARE study. Int J Chron Obstruct Pulmon Dis. 13: 
1377-1388.  
23. Kocakaya D, Yildizeli SO, Arikan H, Erbayat Y, Hıdıroglu S, Gülhan R, Ceyhan 
BB, Eryüksel E (2017). The relationship between symptom scores and medication 







24. Ágh T, Dömötör P, Bártfai Z, Inotai A, Fujsz E, Mészáros Á (2015). Relationship 
between medication adherence and health-related quality of life in subjects with COPD: 
a systematic review.  Respir Care. 60: 297-303.  
25. Boland MR, van Boven JF, Kruis AL, Chavannes NH, van der Molen T, Goossens 
LM5 Rutten-van Mölken MP (2016). Investigating the association between medication 
adherence and health-related quality of life in COPD: Methodological challenges when 
using a proxy measure of adherence. Respir Med. 110: 34-45.  
26. Tülüce D, Kutlutürkan S (2018). The effect of health coaching on treatment 
adherence, self-efficacy, and quality of life in patients with chronic obstructive 
pulmonary disease. Int J Nurs Pract. 24: e12661.  
27. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK 
(2008). Medication compliance and persistence: terminology and definitions. Value 
Health. 11: 44-7.   
28. WHO (2003). ADHERENCE TO LONG-TERM THERAPIES: EVIDENCE FOR 
ACTION.  https://www.who.int/chp/knowledge/publications/adherence_report/en/.  
29. Chakrabarti S (2014). What’s in a name? Compliance, adherence and concordance 
in chronic psychiatric disorders. World J Psychiatry. 4: 30–36.   
30. Theofilou P (2013). Quality of Life: Definition and Measurement. Eur J of Psych. 
9: 150-162.  
31. Mannino DM, Higuchi K, Yu TC, Zhou H, Li Y, Tian H, Suh K (2015). Economic 
Burden of COPD in the Presence of Comorbidities. Chest. 148: 138-150.  
32. Mannino DM, Buist AS (2007). Global burden of COPD: risk factors, prevalence, 
and future trends. Lancet. 370: 765-73.  
33. Terzikhan N, Verhamme KM, Hofman A, Stricker BH, Brusselle GG, Lahousse L 
(2016). Prevalence and incidence of COPD in smokers and non-smokers: the Rotterdam 
Study. Eur J Epidemiol. 31:785–792.  
34. Srivastava K, Thakur D, Sharma S, Punekar YS (2015). Systematic review of 
humanistic and economic burden of symptomatic chronic obstructive pulmonary 
disease. Pharmacoeconomics. 33: 467-88.  
35. Bunker JM, Reddel HK, Dennis SM, Middleton S, Van Schayck C, Crockett AJ, 
Hasan I, Hermiz O, Vagholkar S, Marks GB, Zwar NA (2012). A pragmatic cluster 
randomized controlled trial of early intervention for chronic obstructive pulmonary 








36. Patel JG, Coutinho AD, Lunacsek OE, Dalal AA (2018). COPD affects worker 
productivity and health care costs. Int J Chron Obstruct Pulmon Dis. 13: 2301–2311.  
37. Broemeling AM, Black C (2005). Chronic conditions and co-morbidity among 
residents of British Columbia. s.l. : Centre for Health Services and Policy Research. 
38. Decramer M, Miravitlles M, Price D, Román-Rodríguez M, Llor C, Welte T, Buhl 
R, Dusser D, Samara K, Siafakas N (2011). New horizons in early stage COPD--
improving knowledge, detection and treatment. Respir Med. 105: 1576-87.  
39. Kontz K, Tomisa G, Szenasi G, Farkas A (2016). Characteristics of medical care of 
asthma and COPD patients in the Hungarian healthcare system. [Asztmás és COPD-s 
betegek ellátásának jellemzői a magyar egészségügyben.]. Medicina thoracalis. 69: 
243-251. [Hungarian].  
40. Fromer L, Barnes T, Garvey C, Ortiz G, Saver DF, Yawn B (2010). Innovations to 
achieve excellence in COPD diagnosis and treatment in primary care. Postgrad Med. 
122: 150-64.  
41. Walters JA, Hansen EC, Walters EH, Wood-Baker R (2008). Under-diagnosis of 
chronic obstructive pulmonary disease: a qualitative study in primary care. Respir Med. 
102: 738-43.  
42. Aisanov Z, Bai C, Bauerle O, Colodenco FD, Feldman C, Hashimoto S, Jardim J, 
Lai CK, Laniado-Laborin R, Nadeau G, Sayiner A, Shim JJ, Tsai YH, Walters RD, 
Waterer G (2012). Primary care physician perceptions on the diagnosis and management 
of chronic obstructive pulmonary disease in diverse regions of the world. Int J Chron 
Obstruct Pulmon Dis. 7: 271-282.  
43. Johnston NW, Lambert K, Hussack P, de Verdier MG, Higenbottam T, Lewis J, 
Newbold P, Jenkins M, Norman GR, Coyle PV, McIvor RA (2013). Detection of COPD 
Exacerbations and compliance with patient-reported daily symptom diaries using a 
smart phone-based information system [corrected]. Chest. 144: 507-514.  
44. Partridge MR, Dal Negro RW, Olivieri D (2011). Understanding patients with 
asthma and COPD: insights from a European study. Prim Care Respir J. 20: 315-23,.  
45. Chavez PC, Shokar NK (2009). Diagnosis and management of chronic obstructive 
pulmonary disease (COPD) in a primary care clinic. COPD. 6: 446-451.  
46. Donner CF, Virchow JC, Lusuardi M (2011). Pharmacoeconomics in COPD and 







47. Cavaillès A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-
Adam S, Meurice JC, Morel H, Person-Tacnet C, Leroyer C, Diot P (2013). 
Comorbidities of COPD. Eur Respir Rev. 22: 454-75.  
48. Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G (2010). Prevalence of 
comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 80: 
112-119.  
49 (2007), Melani AS. Inhalatory therapy training: a priority challenge for the physician. 
Acta Biomed. 78: 233-245.  
50. Almagro P, Castro A (2013). Helping COPD patients change health behavior in 
order to improve their quality of life. Int J Chron Obstruct Pulmon Dis. 8: 335-45.  
51. Chrystyn H, Small M, Milligan G, Higgins V, Gil EG, Estruch J (2014). Impact of 
patients' satisfaction with their inhalers on treatment compliance and health status in 
COPD. Respir Med. 108: 358-65.  
52. Resnikoff PM (1998). Getting the most out of a 15-minute visit for COPD. 
https://www.researchgate.net/scientific-contributions/35104529_P_M_Resnikoff [last 
accessed 16/4/2020] 
53. Almagro P, Castro A (2013). Helping COPD patients change health behavior in 
order to improve their quality of life. Int J Chron Obstruct Pulmon Dis. 8: 335-345.  
54. Agusti AG (2005). COPD, a multicomponent disease: implications for management. 
Respir Med. 99: 670-82.  
55. Barnes PJ, Celli BR (2009). Systemic manifestations and comorbidities of COPD. 
Eur Respir J. 33: 1165-85.  
56. Barnes PJ (2008). Immunology of asthma and chronic obstructive pulmonary 
disease. Nat Rev Immunol. 8: 183-92.  
57. GOLD Committee (2019). Global Strategy for the Diagnosis, Management and 
Prevention of COPD.  https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-
v1.7-FINAL-14Nov2018-WMS.pdf [last accessed 16/4/2020] 
58. Bozinovski S, Anthony D, Vlahos R (2014). Targeting pro-resolution pathways to 
combat chronic inflammation in COPD. J Thorac Dis. 6: 1548-1556.  
59. Chung KF (2005). The role of airway smooth muscle in the pathogenesis of airway 








60. Lapperre TS, Sont JK, van Schadewijk A, Gosman MM, Postma DS, Bajema IM, 
Timens W, Mauad T, Hiemstra PS and (2007), GLUCOLD Study Group. Smoking 
cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. Respir 
Res. 8:85.  
61. Anecchino C, Rossi E, Fanizza C, De Rosa M, Tognoni G, Romero M and (2007), 
working group ARNO project. Prevalence of chronic obstructive pulmonary disease and 
pattern of comorbidities in a general population. Int J Chron Obstruct Pulmon Dis. 2: 
567-74.  
62. Burgel PR, Escamilla R, Perez T, Carré P, Caillaud D, Chanez P, Pinet C, Jebrak G, 
Brinchault G, Court-Fortune I, Paillasseur JL, Roche N and (2013), INITIATIVES 
BPCO Scientific Committee. Impact of comorbidities on COPD-specific health-related 
quality of life. Respir Med. 107: 233-41.  
63. Laniado-Laborín R, Rendón A, Alcantar-Schramm JM, Cazares-Adame R, Bauerle 
O (2013). Subutilization of COPD guidelines in primary care: a pilot study. J Prim Care 
Community Health. 4: 172-176.  
64. Miller J, Edwards LD, Agustí A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim 
C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Vestbo J, Wouters 
E, Yates JC, Macnee W and (2013), ECLIPSE Investigators. Comorbidity, systemic 
inflammation and outcomes in the ECLIPSE cohort. Respir Med. 107: 1376-1384.  
65. Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel PL, 
Rutten EP, Op 't Roodt J, Wouters EF, Franssen FM (2013). Clusters of comorbidities 
based on validated objective measurements and systemic inflammation in patients with 
chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 187: 728-35.  
66. van Boven JFM, Román-Rodríguez M, Palmer JF, Toledo N, Cosío BG, Soriano JB 
(2015). Prevalence of comorbidities in patients with asthma-COPD overlap syndrome 
(ACOS) in primary care. European Respiratory Journal 46: OA4786.  
67. Barrecheguren M, Esquinas C, Miravitlles M. The asthma-chronic obstructive 
pulmonary disease overlap syndrome (ACOS): opportunities and challenges. Curr Opin 
Pulm Med. 21: 74-79.  
68 GINA & GOLD (2015). Asthma-COPD Overlap Syndrome (ACOS) and the New 
GOLD Classification.  
https://www.mscbs.gob.es/organizacion/sns/planCalidadSNS/pdf/GOLD_ACOS_2015.







69. Kendzerska T, Sadatsafavi M, Aaron SD, To T, Lougheed MD, FritzGerald JM, 
Gershon AS (2015). Trends in Asthma- Chronic Obstructive Pulmonary Disease 
Overlap Syndrome Prevalence, Incidence and Mortality in Ontario, Canada: A 
Population Study. American Journal of Respiratory and Critical Care Medicine 191: 
A6165.  
70. Nozaki Y, Wakayama H, Yamamoto M, Gen S, Morosawa M, Katoh S, Noda K, 
Ryuge Y (2016). Is Inhaled Corticoid Steroid Therapy One of Keywords for Overlap 
Syndrome Between Asthma and COPD Management? American Journal of Respiratory 
and Critical Care Medicine 193: A6252.  
71. Hassan HA, Aziz NA, Hassan Y, Hassan F (2014). Does the duration of smoking 
cessation have an impact on hospital admission and health-related quality of life 
amongst COPD patients? Int J Chron Obstruct Pulmon Dis. 9: 493–499.  
72. Suh ES, Mandal S, Hart N (2013). Admission prevention in COPD: non-
pharmacological management. BMC Med. 11: 247.  
73. Solanes I, Güell R, Casan P, Sotomayor C, Gonzalez A, Feixas T, Gonzalez M, 
Guyatt G (2009). Duration of pulmonary rehabilitation to achieve a plateau in quality of 
life and walk test in COPD. Respir Med. 103: 722-728.  
74. Kon SS, Canavan JL, Jones SE (2014). Minimum clinically important difference for 
the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2: 195-203.  
75. Lemmens KM, Nieboer AP, Huijsman R (2008). Designing patient-related 
interventions in COPD care: empirical test of a theoretical model. Patient Educ Couns. 
72: 223-31.  
76. Papaioannou AI, Loukides S, Gourgoulianis KI, Kostikasa K (2009). Global 
assessment of the COPD patient: Time to look beyond FEV1? Respiratory Medicine. 
103: 650-660.  
77. Braido F, Baiardini I, Cazzola M, Brusselle G, Marugo F, Canonica GW (2013). 
Long-acting bronchodilators improve health related quality of life in patients with 
COPD. Respir Med. 107: 1465-1480.  
78. Di Martino M, Ventura M, Cappai G, Lallo A, Davoli M, Agabiti N, Fusco D (2017). 
Adherence to Long-Acting Bronchodilators After Discharge for COPD: How Much of 
the Geographic Variation is Attributable to the Hospital of Discharge and How Much to 
the Primary Care Providers? COPD. 14: 86-94.  
79. Bjerg A, Lundbäck B, Lotvall J (2012). The future of combining inhaled drugs for 







80. Dhillon, S (2016). Tiotropium/Olodaterol: A Review in COPD. Drugs. 76: 135-46.  
81. Dawes M (2010). Co-morbidity: we need a guideline for each patient not a guideline 
for each disease. Fam Pract. 27: 1-2.  
82. van der Bemt L, Schermer T, Smeele I, Bischoff E, Jacobs A, Grol R, van Weel C 
(2008). Monitoring of patients with COPD: a review of current guidelines' 
recommendations. Respir Med. 102: 633-41.  
83. Cazzola M, Segreti A, Stirpe E, Puxeddu E, Ora J, Rogliani P, Matera MG (2013). 
Effect of an additional dose of indacaterol in COPD patients under regular treatment 
with indacaterol. Respir Med. 107: 107-111.  
84. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J (2008). 
Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 
6-month study. Respir Med. 102: 1511-20.  
85. Agusti AG (2005). COPD, a multicomponent disease: implications for management. 
Respir Med. 99: 670-682.  
86. Albertson TE, Harper R, Murin S, Sandrock C (2015). Patient considerations in the 
treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol. 
Patient Prefer Adherence. 9: 235–242.  
87. Babu KS, Kastelik JA, Morjaria JB (2014). Inhaled corticosteroids in chronic 
obstructive pulmonary disease: a pro-con perspective. Br J Clin Pharmacol. 78: 282-
300.  
88. Gyires Klára, Fürst Zsuzsanna, Ferdinandy Péter. Farmakológia és klinikai 
farmakológia. Budapest : Medicina, 2018. pp. 297-315 
89. Moher D1, Liberati A, Tetzlaff J, Altman DG and (2009), PRISMA Group. Preferred 
reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann 
Intern Med. 151: 264-9.  
90. Grover A, Joshi A (2014). An overview of chronic disease models: a systematic 
literature review. Glob J Health Sci. 7: 210-27.  
91. Koivunen M, Saranto K (2018). Nursing professionals' experiences of the facilitators 
and barriers to the use of telehealth applications: a systematic review of qualitative 
studies. Scand J Caring Sci. 32: 24-44.  
92. Zeki A, Raad HK (2015). Telemedicine: Emerging Technologies, Applications and 







93. Blumenthal JA, Emery CF, Smith PJ, Keefe FJ, Welty-Wolf K, Mabe S, Martinu T, 
Johnson JJ, Babyak MA, O'Hayer VF, Diaz PT, Durheim M, Baucom D, Palmer SM 
(2014). The effects of a telehealth coping skills intervention on outcomes in chronic 
obstructive pulmonary disease: primary results from the INSPIRE-II study. Psychosom 
Med. 76: 581-92.  
94. Stellefson M, Chaney B, Ochipa K, Chaney D, Haider Z, Hanik B, Chavarria E, 
Bernhardt JM (2014). YouTube as a source of COPD patient education: A social media 
content analysis. Chron Respir Dis. 11: 61–71.  
95. Bourbeau J, van der Palen J (2009). Promoting effective self-management 
programmes to improve COPD. Eur Respir J. 33: 461-3.   
96. Wang CH, Chou PC, Joa WC, Chen LF, Sheng TF, Ho SC, Lin HC, Huang CD, 
Chung FT, Chung KF, Kuo HP (2014). Mobile-phone-based home exercise training 
program decreases systemic inflammation in COPD: a pilot study. BMC Pulm Med. 14: 
142.  
97. Au DH, Macaulay DS, Jarvis JL, Desai US, Birnbaum HG (2015). Impact of a 
telehealth and care management program for patients with chronic obstructive 
pulmonary disease. Ann Am Thorac Soc. 12: 323-331.  
98. Barr RG, Celli BR, Martinez FJ, Ries AL, Rennard SI, Reilly JJ, Sciurba FC, 
Thomashow BM, Wise RA (2015). Physician and patient perceptions in COPD: the 
COPD Resource Network Needs Assessment Survey. Am J Med. 118: 1415.  
99. Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R, Vines DL, 
Sikkema-Ortiz J, Gardner DD, Wilkins RL (2008). Medication adherence issues in 
patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 3: 71-84.  
100. Kale MS, Federman AD, Krauskopf K, Wolf M, O'Conor R, Martynenko M, 
Leventhal H, Wisnivesky JP (2015). The Association of Health Literacy with Illness 
and Medication Beliefs among Patients with Chronic Obstructive Pulmonary Disease. 
PLoS One. 10: e0123937.  
101. Gallefos F (2004). The effects of patient education in COPD in a 1-year follow-up 
randomised, controlled trial. Patient Educ and Couns. 52: 259-66.  
102. Guo SE, Bruce A (2014). Improving understanding of and adherence to pulmonary 
rehabilitation in patients with COPD: a qualitative inquiry of patient and health 







103. Effing T, Monninkhof EM, van der Valk PD, van der Palen J, van Herwaarden CL, 
Partidge MR, Walters EH, Zielhuis GA (2007). Self-management education for patients 
with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 4: 
CD002990.  
104. Bourbeau J, Lavoie KL, Sedeno M (2015). Comprehensive Self-Management 
Strategies. Semin Respir Crit Care Med. 36: 630-638.   
105. Küver C, Beyer M, Gensichen J, Ludt S, Schmitz A, Szecsenyi J, Gerlach FM 
(2004). [An assessment of patient education programmes for patients with type 1 and 2 
diabetes, asthma and COPD, coronary heart disease, hypertension, congestive heart 
failure, and breast cancer in Germany]. Z Arztl Fortbild Qualitatssich. 98: 393-402.  
106. Clari M, Matarese M, Alvaro R, Piredda M, De Marinis MG (2016). Measurement 
properties of instruments evaluating self-care and related concepts in people with 
chronic obstructive pulmonary disease: A systematic review. Heart Lung. 45: 441-8.  
107. Reddel HK, Jenkins CR, Partridge MR (2014). Self-management support and other 
alternatives to reduce the burden of asthma and chronic obstructive pulmonary disease. 
Int J Tuberc Lung Dis. 18: 1396-406.  
108. An MH, Choi JY (2012). Relationship of Knowledge, Attitude, Correct Metered 
Dose Inhaler Use, and Self-management Compliance among Patients with COPD. 
Korean Journal of Adult Nursing 24: 2.  
109. Chang YY, Dai YT, Chien NH, Chan HY (2016). The Lived Experiences of People 
With Chronic Obstructive Pulmonary Disease: A Phenomenological Study. J Nurs 
Scholarsh. 48: 466-71.   
110. Neri M (2008). COPD patient's education and self-management teaching: a 
worthwhile effort? Monaldi Arch Chest Dis. 69: 47-49.  
111. Davis E, Marra C, Gamble JM, Farrell J, Lockyer J, FitzGerald JM, Abu-Ashour 
W, Gillis C, Hawboldt J (2016). Effectiveness of a pharmacist-driven intervention in 
COPD (EPIC): study protocol for a randomized controlled trial. Trials. 17: 502.  
112. Khdour MR, Kidney JC, Smyth BM, McElnay JC (2009). Clinical pharmacy-led 
disease and medicine management programme for patients with COPD. Br J Clin 
Pharmacol. 68: 588-98.  
113. Sari N, Osman M (2015). The effects of patient education programs on medication 
use among asthma and COPD patients: a propensity score matching with a difference-







114. van der Molen T, van Boven JF, Maguire T, Goyal P, Altman P (2017). Optimizing 
identification and management of COPD patients - reviewing the role of the community 
pharmacist. Br J Clin Pharmacol. 83: 192-201.  
115. Hämmerlein A, Müller U, Schulz M (2011). Pharmacist-led intervention study to 
improve inhalation technique in asthma and COPD patients. J Eval Clin Pract. 17: 61-
70.  
116. Tommelein E, Mehuys E, Van Hees T, Adriaens E, Van Bortel L, Christiaens T, 
Van Tongelen I, Remon JP, Boussery K, Brusselle G (2014). Effectiveness of 
pharmaceutical care for patients with chronic obstructive pulmonary disease 
(PHARMACOP): a randomized controlled trial. Br J Clin Pharmacol. 77: 756-66.   
117. Miravitlles M, Ferrer J, Baró E, Lleonart M, Galera J (2013). Differences between 
physician and patient in the perception of symptoms and their severity in COPD. Respir 
Med. 107: 1977-85.  
118. Brien SB, Lewith GT, Thomas M (2016). Patient coping strategies in COPD across 
disease severity and quality of life: a qualitative study. NPJ Prim Care Respir Med. 26: 
16051.  
119. Trivedi RB, Bryson CL, Udris E, Au DH (2012). The influence of informal 
caregivers on adherence in COPD patients. Ann Behav Med. 44: 66-72.  
120. Lange P, Andersen KK, Munch E, Sørensen TB, Dollerup J, Kassø K, Larsen HB, 
Dahl R (2009). Quality of COPD care in hospital outpatient clinics in Denmark: The 
KOLIBRI study. Respir Med. 103: 1657-62.  
121. Monteagudo M, Rodríguez-Blanco T, Llagostera M, Valero C, Bayona X, Ferrer 
M, Miravitlles M (2013). Factors associated with changes in quality of life of COPD 
patients: a prospective study in primary care. Respir Med. 107: 1589-1597.  
122. Steurer-Stey C, Markun S, Lana KD, Frei A, Held U, Wensing M, Rosemann T 
(2014). The improving care in chronic obstructive lung disease study: CAROL 
improving processes of care and quality of life of COPD patients in primary care: study 
protocol for a randomized controlled trial. Trials. 15: 96.   
123. Perez T, Serrier P, Pribil C, Mahdad A (2013). COPD and quality of life: Impact 
of the disease in primary care in France. Revue des Maladies Respiratoires. 30: 22-32.  
124. Ninot G, Moullec G, Picot MC, Jaussent A, Hayot M, Desplan M, Brun JF, Mercier 
J, Prefaut C (2011). Cost-saving effect of supervised exercise associated to COPD self-







125. Tøttenborg SS, Lange P, Johnsen SP, Nielsen H, Ingebrigtsen TS, Thomsen RW 
(2016). Socioeconomic inequalities in adherence to inhaled maintenance medications 
and clinical prognosis of COPD. Respir Med. 119: 160-167.  
126. VanderSchaaf K, Olson KL, Billups S, Hartsfield CL, Rice M (2010). Self-reported 
inhaler use in patients with chronic obstructive pulmonary disease. Respir Med. 104: 
99-106.  
127. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, Serra M, 
Scichilone N, Sestini P, Aliani M, Neri M, AIPO (2011). Inhaler mishandling remains 
common in real life and is associated with reduced disease control. Resp Med. 105: 930-
938.  
128. Negro RWD, Bonadiman L, Turco P, Tognella S, Iannazzo S (2015). Costs of 
illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): 
an update. Clinicoecon Outcomes Res. 7: 153–159.  
129. Donner CF, Lusuardi M (2010). COPD a social disease: inappropriateness and 
pharmaco-economics. The role of the specialist: present and future. Multidiscip Respir 
Med. 5: 437–449.  
130. Jansson SA, Backman H, Stenling A, Lindberg A, Rönmark E, Lundbäck B (2013). 
Health economic costs of COPD in Sweden by disease severity--has it changed during 
a ten years period? Respir Med. 107: 1931-8.  
131. Incorvaia C, Riario-Sforza GG (2011). Effect of patient education on adherence to 
drug treatment for chronic obstructive pulmonary disease. Ann Thorac Med. 6: 242–
243.  
132. Krauskopf K, Federman AD, Kale MS, Sigel KM, Martynenko M, O'Conor R, 
Wolf MS, Leventhal H, Wisnivesky JP (2015). Chronic Obstructive Pulmonary Disease 
Illness and Medication Beliefs are Associated with Medication Adherence. COPD. 12: 
151-64.   
133. van Boven JF, Chavannes NH, van der Molen T, Rutten-van Mölken MP, Postma 
MJ, Vegter S (2014). Clinical and economic impact of non-adherence in COPD: a 
systematic review. Respir Med. 108: 103-13.   
134. Inotai A, Kaló Z, Lovas K (2014). Az egészségnyereség mérése - A betegek 
értékelése alapján.  
135. Coons SJ, Rao S, Keininger DL, Hays RD (2000). A comparative review of generic 







136. Wacker ME, Jörres RA, Karch A, Wilke S, Heinrich J, Stefan Karrasch, Armin 
Koch, Holger Schulz, Henrik Watz, Reiner Leidl, Claus Vogelmeier, Rolf Holle, 
COSYCONET (2016). Assessing health-related quality of life in COPD: comparing 
generic and disease-specific instruments with focus on comorbidities. BMC Pulm Med. 
16: 70. 
137. van der Molen T, Diamant Z, Kocks JW, Tsiligianni IG (2014). The use of health 
status questionnaires in the management of chronic obstructive pulmonary disease 
patients in clinical practice. Expert Rev Respir Med. 8: 479-91. 
138. Agusti A, Soler-Cataluña JJ, Molina J, Morejon E, Garcia-Losa M, Roset M, Badia 
X (2015). Does the COPD assessment test (CAT(TM)) questionnaire produce similar 
results when self- or interviewer administered? Qual Life Res. 24: 2345-54. 
139. George J, Kong DC, Stewart K (2007). Adherence to disease management 
programs in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2: 253-62. 
140. Nguyen TM, La Caze A, Cottrell N (2014). What are validated self-report 
adherence scales really measuring: a systematic review. Br J Clin Pharmacol. 77: 427-
45. 
141. Lam WY, Fresco P (2015). Medication Adherence Measures: An Overview. 
Biomed Res Int. 2015: 217047. 
142. Tan X, Patel I, Chang J (2014). Review of the four item Morisky Medication 
Adherence Scale (MMAS-4) and eight item Morisky Medication Adherence Scale 
(MMAS-8). INNOVATIONS in pharmacy. 5: 165. 
143. Rosenthal M (2016). Qualitative research methods: Why, when, and how to 
conduct interviews and focus groups in pharmacy research. Currents in Pharmacy 
Teaching and Learning. 8: 509-516.  
144. KSH (2019). Magyarország közigazgatási helynévkönyve. 
http://www.ksh.hu/docs/hun/hnk/hnk_2019.pdf [last accessed 16/4/2020] 
145. Rosenthal, M (2016). Qualitative research methods: Why, when, and how to 
conduct interviews and focus groups in pharmacy research. Volume 8, Issue 4, Pages 
509-516. https://doi.org/10.1016/j.cptl.2016.03.021. 
146. Bovea DG, Midtgaard J, Kaldana G, Overgaard D, Lomborgef K (2017). Home-
based COPD psychoeducation: A qualitative study of the patients' experiences. Journal 
of Psychosomatic Research. 98: 71-77.  
147. Gupta N, Pinto LM, Morogan A, Bourbeau J (2014). The COPD assessment test: 







148. Stoilkova-Hartmann A, Franssen FME, Augustin IML, Wouters EFM, Barnard KD 
(2018). COPD patient education and support – achieving patient-centredness. Patient 
Educ Couns. 10: 2031-2036.  
149. Wang L, Mårtensson J, Zhao Y, Nygårdh A (2018). Experiences of a health 
coaching self-management program in patients with COPD: a qualitative content 
analysis. Int J Chron Obstruct Pulmon Dis. 13: 1527-1536.  
150. Hansen H, Bieler T, Beyer N, Godtfredsen N, Kallemose T, Frølich A (2017). 
COPD online-rehabilitation versus conventional COPD rehabilitation – rationale and 
design for a multicenter randomized controlled trial study protocol (CORe trial). BMC 
Pulm Med. 17: 140.  
151. Oguzulgen I, Kokturk N, Isikdogan Z (2014). Turkish validation study of Morisky 
8-item medication adherence questionnaire (MMAS-8) in patients with asthma and 
chronic obstructive pulmonary disease. Tuberk Toraks. 62: 101-107.  
152. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D (2011). Development 
and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life 
Res. 20: 1727-1736.  
153. Dolan P (1997). Modeling valuations for EuroQol health states. Med Care. 35: 
1095-1108.  
154. EuroQol Group (1990). EuroQol–a new facility for the measurement of health-
related quality of life. Health Policy. 16: 199-208.  
155. Jones PW, Quirk FH, Baveystock CM (1991). The St. George’s Respiratory 
Questionnaire. Respir Med. 85: 25-31; discussion 33-37.  
156. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N (2009). 
Development and first validation of the COPD Assessment Test. Eur Respir J. 34: 648-
654.  
157. Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008). Predictive validity of a 
medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 
10: 348-354.  
158. Morisky DE, DiMatteo MR (2011). Improving the measurement of self-reported 
medication nonadherence: response to authors. J Clin Epidemiol. 64: 255-257.   
159. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P (2009). 
New medication adherence scale verrus pharmacy fill rates in seniors with hypertension. 







160. van Voorhis C, Morgan B (2007). Understanding power and rules of thumb for 
determining sample sizes. Tutorials in Quantitative Methods for Psychology. 3: 43-50.  
161. Sharp MK, Utrobičić A, Gómez G, Cobo E, Wager E, Hren D (2017). The STROBE 
extensions: protocol for a qualitative assessment of content and a survey of 
endorsement. BMJ Open. 7: e019043. 
162. Kovács G (2016). Official opinion of the Hungarian Society of Pulmonologists. 
http://medicalonline.hu/gyogyitas/cikk/ tudogyogyaszat__2016. 
163. Chakrabarti S (2014). What’s in a name? Compliance, adherence and concordance 
in chronic psychiatric disorders. World J Psychiatry. 4: 30–36. 
164. Seemungal TAR, Wedzicha JA (2006). Integrated care: a new model for COPD 
management? European Respiratory Journal. 28: 4-6. 
165. Thabane M, and COPD Working Group (2102). Smoking Cessation for Patients 
With Chronic Obstructive Pulmonary Disease (COPD). Ont Health Technol Assess Ser. 
12: 1–50. 
166. Cameron-Tucker HL, Wood-Baker R, Joseph L, Walters JA, Schüz N, Walters EH 
(2016). A randomized controlled trial of telephone-mentoring with home-based walking 
preceding rehabilitation in COPD. Int J Chron Obstruct Pulmon Dis. 11: 1991–2000. 
167. Brown VT, Patel I, Thomas N, Tomlinson J, Roberts R, Rayner H, Ashman N, 
Hulla S (2017). New ways of working; delivering better care for people with long-term 
conditions. London J Prim Care (Abingdon). 9: 60–68. 
168. García-Río F, Soler-Cataluña JJ, Alcazar B, Viejo JL, Miravitlles M (2017). 
Requirements, Strengths and Weaknesses of Inhaler Devices for COPD Patients from 
the Expert Prescribers' Point of View: Results of the EPOCA Delphi Consensus. COPD. 
14: 573-580.  
169. Rogliani P, Ora J, Puxeddu E, Matera MG, Cazzola M (2017). Adherence to COPD 
treatment: Myth and reality. Respir Med. 129: 117-123.  
170. Nakken N, Janssen DJA, van den Bogaart EHA, Muris JWM, Vercoulen JH, 
Custers FL, Bootsma GP, Gronenschild MHM, Wouters EFM, Spruit MA (2017). 
Knowledge gaps in patients with COPD and their proxies. BMC Pulm Med. 17: 136.  
171. Enocson A, Jolly K, Jordan RE, Fitzmaurice DA, Greenfield SM, Adab P (2018). 
Case-finding for COPD in primary care: a qualitative study of patients’ perspectives. Int 







172. Corhay JL, Dang DN, Cauwenberge HV, Louis R (2014). Pulmonary rehabilitation 
and COPD: providing patients a good environment for optimizing therapy. Int J Chron 
Obstruct Pulmon Dis. 9: 27–39.  
173. Hawken N, Torvinen S, Neine ME, Amri I, Toumi M, Aballéa S, Plich A, Roche 
N (2017). Patient preferences for dry powder inhaler attributes in asthma and chronic 
obstructive pulmonary disease in France: a discrete choice experiment. BMC Pulm Med. 
17: 99.  
174. Bollmeier SG, Seaton TL, Prosser TR, Chou YT, Reckenberg K, Hahn B, Stanford 
RH, Ray R (2019). Assessment of symptom burden and adherence to respiratory 
medications in individuals self-reporting a diagnosis of COPD within a community 
pharmacy setting. Journal of the American Pharmacists Association. 59: 479-488.  
175. Axtell S, Haines S, Fairclough J (2017). Effectiveness of Various Methods of 
Teaching Proper Inhaler Technique: The Importance of Pharmacist Counseling. J 
Pharm Pract. 30: 195-201.  
176. Yamada K, Nabeshima T (2015). Pharmacist-managed clinics for patient education 
and counseling in Japan: current status and future perspectives. J Pharm Health Care 
Sci. 1: 2.  
177. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ, Mpex 204 Study 
Group (2011). Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis 
with Pseudomonas aeruginosa.  Am J Respir Crit Care Med. 183: 1510–1516.  
178. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, 
Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL (1999). 
Validation of the treatment satisfaction questionnaire for medication in patients with 
cystic fibrosis. N Engl J Med. 340: 23–30.  
179. Regnault A, Balp MM, Kulich K, Viala-Danten M (2012). Validation of the 
treatment satisfaction questionnaire for medication in patients with cystic fibrosis. J 
Cyst Fibros. 11: 494–501.  
180. Harrison MJ, McCarthy M, Fleming C, Hickey C, Shortt C, Eustace JA, Murphy 
DM, Plant BJ (2014). Inhaled versus nebulised tobramycin: a real world comparison in 
adult cystic fibrosis (CF). J Cyst Fibros. 13: 692-698.  
181. Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL (2006). A 
multimethod assessment of treatment adherence for children with cystic fibrosis. J Cyst 







182. Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, 
Montgomery AB, Cooper PJ (2010). An 18-month study of the safety and efficacy of 
repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol. 45: 
1121–1134.  
183. Briesacher BA, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quittell LM (2011). 
Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm 
Med. 11: 5.  
184. Eakin MN, Bilderback A, Boyle MP, Mogayzel PJ, Riekert KA (2011). 
Longitudinal association between medication adherence and lung health in people with 
cystic fibrosis. J Cyst Fibros. 10: 258–264.  
185. McNamara PS, McCormack P, McDonald AJ, Heaf L, Southern KW (2009). Open 
adherence monitoring using routine data download from an adaptive aerosol delivery 
nebuliser in children with cystic fibrosis. J Cyst Fibros. 8: 258–263.  
186. Wertz DA, Chang CL, Stephenson JJ, Zhang J, Kuhn RJ (2011). Economic impact 
of tobramycin in patients with cystic fibrosis in a managed care population. J Med Econ. 
14: 759–768.   
187. Ágh Tamás (2012). Terápiahűség, életminőség és betegségteher krónikus 
obstruktív tüdőbetegségben. DOKTORI ÉRTEKEZÉS. Semmelweis Egyetem, 
Gyógyszertudományok Doktori Iskola. DOI: 10.14753/SE.2013.1809. Chapter Results 
188. Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ (2013). Patient 
characteristics associated with medication adherence. Clin Med Res. 11: 54-65.  
189. Marks JR, Schectman JM, Groninger H, Plews-Ogan ML (2010). The association 
of health literacy and socio-demographic factors with medication knowledge. Patient 
Educ Couns. 78: 372-376.  
190. Okuyan B, Sancar M, Izzettin FV (2013). Assessment of medication knowledge 
and adherence among patients under oral chronic medication treatment in community 
pharmacy settings. Pharmacoepidemiol Drug Saf. 22: 209-214.  
191. Alkhateri AM, Albekairy AM (2013). Does the patients’ educational level and 
previous counseling experience affect their medication knowledge? Ann Thorac Med. 
8: 105-108.  
192. Appel GB (1990). Aminoglycoside nephrotoxicity. Am J Med. 88: 16-20.  
193. Chuchalin A, Amelina E, Bianco F (2009). Tobramycin for inhalation in cystic 







194. Hilliard ME, Hahn A, Ridge AK, Eakin MN, Riekert KA (2014). User preferences 
and design recommendations for an mHealth app to promote cystic fibrosis self-
management. JMIR. 2: e44.  
195. Heaney LG, McGarvey LP (2017). Personalised Medicine for Asthma and Chronic 
Obstructive Pulmonary Disease. Respiration. 93: 153-161.  
196. Chuang C, Levine S, Rich J (2011). Enhancing cost-effective care with a patient-
centric chronic obstructive pulmonary disease program. Popul Health Manag. 14: 133-
136.   
 
Additional sources used for the compilation of figures and tables, which are not my 
work. Mate Olah and Szilvia Kresznerits created all other diagrams. 
Figure 2 has been taken from (55).  














10. List of publications 
10.1. Publications relevant to the dissertation 
(1) Oláh M, Kresznerits Sz, Gonda X, Perczel-Forintos D, Szabó M, Csánky E, 
Mészáros Á (2020) Impact of education on dimensions of adherence in patients 
with chronic obstructive pulmonary disease.  Acta Poloniae Pharmaceutica 77: 
195-204. IF2018=0.447 
(2) Oláh M, Kresznerits Sz, Perczel-Forintos D, Kun Cs, Csánky E, Mészáros Á 
(2020) Egy oktatóprogram fejlesztésének lehetőségei tüdőgyógyász szakorvosok 
krónikus obstruktív tüdőbetegséggel kapcsolatos megítélése alapján [Aspects of 
developing an education programme based on pulmonologists’ appraisal related 
to chronic obstructive pulmonary disease]. Orvosi Hetilap 161: 95-102. 
IF2018=0.564 
(3) Oláh M, Inczeffy-Ivicsics K, Mészáros Á (2019) How to design an education 
programme for patients with chronic obstructive pulmonary disease? – Learnings 
from a pilot community pharmacy based project to evaluate patient attitudes. Acta 
Pharmaceutica Hungarica 89: 109-115. 
(4) Oláh M, Mészáros Á (2017) Added value of different healthcare professionals, 
with special regard to pharmacists to COPD therapy experience. Acta 
Pharmaceutica Hungarica 87: 3-4 
(5) Bodnár R, Mészáros Á, Oláh M, Ágh T (2016) Inhaled antibiotics for the 
treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients: 
challenges to treatment adherence and strategies to improve outcomes. Patient 
Prefer Adherence. 10: 183-93. IF2016=1.798 
(6) Ágh T, Bodnár R, Oláh M, Mészáros Á (2015) Adherence to Inhaled Antibiotics 
for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients with 
Cystic Fibrosis: A Systematic Literature Review. Value in Health 18:7 (ISPOR 







10.2. Other publications, not relevant to the dissertation 
(1) Kristof Z, Kresznerits S, Olah M, Gyollai A, Lukacs-Miszler K, Halmai 
T, Fountoulakis KN, Tenyi T, Dome P, Gonda X (2018) Mentalization and 
empathy as predictors of violence in schizophrenic patients: Comparison with 
nonviolent schizophrenic patients, violent controls and nonviolent controls. 









I owe gratitude to Dr. Ágnes Mészáros, my supervisor, for her great contribution to my 
research and attention throughout the publication process.  
I would like to convey my heartfelt gratitude to Prof. Romána Zelkó, whose expert 
opinion, encouraging words and great ability to show direction in research are very 
much appreciated, as well as to finalize this work, as well as the Head of the Doctoral 
School of Pharmaceutical Sciences for the enabling conditions to implement this 
research. 
I would like to offer my deepest appreciation to the pulmonologist team, Dr. Melinda 
Nyírő, Mária Kötél, Gabriella Kupecz, Dr. Gyöngyi Szabó, Zsuzsanna Nagy Karcsainé, 
Dr. Nikolett Popa, Erzsébet Tóth, Dr. Anikó Sipos and Rita Jakab, who helped 
immensely to realize the study. The same huge thanks go the Inczeffy Pharmacy team, 
Katalin Dr. Ivicsics-Inczeffy and Anikó Együd Galgovszkiné. 
My special thanks also go to Szilvia Kresznerits, Dr. Ágnes Kovács and Dr. Attiláné 
Meskó for their expert knowledge in statistical analysis. I am extremely grateful to Szilvi 
for her continuous help to provide the statistical background to the articles, too.  
I would like to grant an imaginary laurel wreath to Dr. Réka Bodnár and Dr. Tamás 
Ágh, who taught me a lot about perseverance and scientific methodology. I am honestly 
grateful to them to have helped me start this journey and set the example ahead.  
I am immensely grateful to Dr. Katalin Kontz for her advice and for all the knowledge 
that she taught me about COPD. My special thanks are extended to Dr. Xénia Gonda, 
Enikő Kovács and Dr. Róbert Csépe for their loyal support.  
Last but not least, I would like to thank my family, my friends and my beloved ones for 
















12.2. Informed consent form 
 A vizsgálat helyszíne:  ...............................................................................  
Vizsgálatvezető neve és beosztása: Mészáros Ágnes PhD egyetemi docens, c. 
egyetemi tanár, Semmelweis Egyetem Egyetemi Gyógyszertár Gyógyszerügyi 
Szervezési Intézet 
A tájékoztatást végző személy:        neve: Dr. Oláh Máté 
                                                         beosztása: gyógyszerész, PhD-hallgató  
 ........................................................... [beteg neve] tájékoztatást kaptam a fenti 
vizsgálatról és elolvastam a mellékelt Betegtájékoztatót. Lehetőségem volt a kapott 
információkat megbeszélni, kérdéseket feltenni. Beleegyezem a vizsgálatban való 
részvételbe és részvételem teljesen önkéntes. Megértettem, hogy beleegyezésemet 
bármikor, indoklás nélkül visszavonhatom, és ez nem befolyásolja ellátásomat.  
Ezen Írásos Beleegyezési Nyilatkozat aláírásával hozzájárulok ahhoz, hogy 
személyes adataimat, beleértve a testi vagy lelki egészségi állapotommal 
kapcsolatos adatokat a Betegtájékoztatóban leírt módon használják fel.  
Engedélyezem, hogy önkéntesen részt kívánok venni a vizsgálatban. Engedélyezem, 
hogy a vizsgálattal kapcsolatosan megadott adataimhoz való hozzáférést, és 
beleegyezem, hogy a kérdésekre adott válaszaimat a kutatás kapcsán közzétett 
kiadványhoz felhasználják a személyazonosságomra vonatkozó bármely adat 
nyilvánossá tétele nélkül. 
  
Résztvevő személy adatai: 
Név:  ..............................................................................  
Születési idő:  ................................................................ kora:  
Lakóhely:  ...................................................................... [település neve] 
Telefonszám: .................................................................  
E-mail:  ..........................................................................  
  
  
………………….…….………                                       ………………………… 
Tájékoztatást végző aláírása                                                dátum 
  
  





















Kérem, az alábbi kérdésekre őszintén válaszoljon! Az erre adott válaszok nem 
befolyásolják a megítélést vagy a programban való részvételt! 
Életkorom (év):       férfi / nő 
Jelenlegi foglalkozásom: 
Legmagasabb iskolai végzettségem: alap / közép / felső 
Társadalmilag ide sorolom a családom helyzetét (húzza alá a megfelelőt!): 
kifejezetten jó körülmények között, az átlagosnál job körülmények között élünk 
megfelelő körülmények között, átlagos szinten élünk 
az átlag alatti életszínvonalon élünk 
nagyon rossz körülmények között élünk 
Dohányzom / nem dohányzom. Ha igen, napi hány szálat? 
A tüdőgyógyászati szereimmel kapcsolatban  
jobban betartom a terápiát / kevésbé tartom be a terápiát, mint más 
gyógyszereimnél.  
elegendő / túl kevés / túl sok információval rendelkezem a használatról. 
A tüdőgyógyászati kontrollra járást  
fontosabbnak / ugyanolyan fontosnak / kevésbé fontosnak tartom, mint a többi 
betegségem kezelését.  
A tüdőgyógyászomban bízok / nem bízok, jó a viszonyunk / lehetne jobb a viszonyunk.  
 
A háziorvosommal jobb / rosszabb / ugyanolyan a viszonyom, mint a tüdőgyógyásszal.  
Bármilyen egyéb hozzáfűznivaló: 
  
Orvos tölti ki! 
A beteg tüdőgyógyászati gyógyszerei: 
 



















































































12.4. Education content 
This chapter demonstrates the education content in a textwise form in Hungarian 
language in order to provide a better insight into the fixed content conveyed to the 
patient in each session.4 
Bevezetés 
A legtöbb ember számára a könnyű légzés magától értetődő, természetesen életfunkció. 
Csak akkor tudatosul bennünk, hogy mennyire kincs a könnyű, szabad légzés, amikor 
már nehezen kapunk levegőt.  
Ha Önnél már COPD-t diagnosztizáltak, akkor bizonyára jól tudja, hogy tudja, hogy 
nem csupán egy dolog, ami meghatározza a közérzetét, illetve azt, hogy mit és milyen 
intenzitással tud csinálni. A COPD olyasvalami, ami befolyásolja a környezetében lévő 
embereket is.  
Mi a COPD? 
A COPD a krónikus obstruktív tüdőbetegség angol elnevezésének a rövidítése (Chronic 
Obstructive Pulmonary Disease). A köztudatban dohányos tüdőként vagy dohányos 
mellkasként szerepel, mert a legtöbb COPD-s jelenleg is aktív dohányos, vagy korábban 
dohányzott.  
C: krónikus vagy idült. Ha már egyszer a betegség kialakult, akkor az már nem múlik 
el, ezzel együtt kell élnie (angolul Chronic).  
O: obstruktív = beszűkült. A tüdőkben lévő légutak beszűkülnek, ami nehezíti a légzést 
is, de különösen a kilégzést (angolul Obstructive).  
P: Tüdővel kapcsolatos (angolul Pulmonary).  
D: A betegség szó kifejezésének (Disease) szóból származik. A betegség alatt a speciális 








Hogyan működik az egészséges tüdő? 
Amikor lélegzünk, a levegőt beszívjuk a tüdőnkbe. A levegő az orrunkon vagy a 
szánkon keresztül egy széles csőbe, a légcsőbe jut, amely a torkunk hátsó részétől a 
mellkasunk közepéig húzódik. A légcső ezután két, valamivel vékonyabb csőre oszlik, 
a jobb és bal főhörgőre, amelyek az elágazás után a jobb és bal tüdőbe lépnek be. Ezt 
követően mindkét főhörgő a faágakhoz hasonlóan oszlik kisebb és kisebb járatokra, 
amíg a levegő eljut egészen a tüdőszövetekig, ahol a gázcsere megtörténik.  
Ezeken a területeken találhatók az úgynevezett alveolusok, magyarul léghólyagocskák, 
ezek olyanok, mint apró, levegővel telt zsebek, amelyek miatt a tüdők megjelenése a 
szivacshoz hasonló. Az alveolusokban tisztul meg a vér a szén-dioxidtól, és frissül fel a 
levegő friss oxigénjével. Ez a légzés folyamata.  
Az egészséges légutak karbantartásáért egyrészt azok az izmok felelnek, amelyek 
kívülről pányvaszerűen tartják nyitva a légutakat, másrészt a hörgőket belülről bélelő 
nyákréteg, amely összegyűjti a belégzett porokat és apró részecskéket, majd kimossa 
azokat.  
Mi történik a COPD-s tüdőben? 
A COPD hosszú évek alatt alakul ki. Rendszerint a légutak nyálkahártyáját tartósan 
irritáló kémiai anyagok okozzák, melyeket a cigarettafüsttel vagy szennyezett levegőből 
lélegzünk be.  
1. A por- és füstszemcsék folyamatos izgató hatása miatt a légutak nyálkahártyája 
károsodik és megduzzad, a beszűkülő légutakon keresztül nehezebben áramlik a 
levegő a tüdőbe.  
 
4 The education content was developed in cooperation with Boehringer Ingelheim Hungary, and 
implemented as an unfunded project. This presented educational content is the intellectual property of 







2. A légúti nyálkahártya nagy mennyiségű váladékot termel, amelyet köpet 
formájában köhögünk fel.  
3. A légutakat körülvevő izmok összehúzódása tovább fokozza a légutak 
szűkületét, így a tüdőbe lélegzett levegő csapdába kerül, nehezedik annak a 
kilégzése. Egyre több elhasznált levegő reked a tüdőkben, ezért kevesebb friss 
levegőt leszünk képesek beszívni.  
Mindezek együttes jelenléte miatt a COPD-ben szenvedő emberek gyakran érzik úgy, 
hogy szorít a mellkasuk, és nem jut elég levegő a tüdejükbe, ezen kívül a fokozott 
váladéktermelés miatt tartós köhögés is kínozza őket.  
Súlyos esetekben a tüdő alveolusai pattanásig feszülnek és sérülnek a beszorult levegő 
nyomásától, így azok már nem képesek ellátni a feladatukat, a szén-dioxid cseréjét. Ezt 
az állapotot emfizémának (tüdőtágulatnak) nevezik, amelyhez a betegség súlyosságától 
függően különböző mértékű légszomj társul.  
Jelek és tünetek 
Nem minden COPD-s betegnél jelentkeznek ugyanazok a tünetek, de az alábbiakból 
legalább egy van: 
- tartós, nem szűnő köhögés 
- produktív köhögés – sűrű köpettel járó köhögés 
- zihálás – mely lehet sípoló vagy hangosan hörgő az egyes légvételeknél 
- légszomj és nehézlégzés – egyeseknél csak fizikai terhelésre, másoknál viszont 
már a házimunka során is jelentkezhet 
- fáradtság, gyengeség, erőtlenség 
- gyakori és nehezen kezelhető légúti fertőzések 
- fogyás 
Miért lettem COPD-s? 
Az Egészségügyi Világszervezet (WHO) becslése alapján világszerte kb. 80 millió 
ember szenved COPD-ben, amely a negyedik vezető halálok a világon. Ez a szám 
tovább fog nőni, ha nem hozzák meg azokat a komoly intézkedéseket, amelyek 







A COPD kialakulását fokozza: 
- néhány foglalkozás, pl. a szénbányászat 
- környezetszennyezés 
- öröklődő betegségek 
Mi súlyosbítja a COPD-t? 
A COPD egy progresszív betegség, ami azt jelenti, hogy az idő előre haladtával 
folyamatosan romlik a beteg állapota. Bizonyos tényezők képesek felgyorsítani ezt a 
folyamatot, mint pl. a cigarettafüst gyakori belégzése, elsősorban az aktív dohányzás, 
de a passzív dohányzás vagy a légszennyezettség is. Amennyiben ezek a tényezők 
megszűnnek, akkor a betegség romlása is lassulhat. Más tényezők is okozhatnak 
exacerbációt, azaz a tünetek fellángolását. A súlyos állapotromlás gyakran megelőzhető 
az alábbi okok kerülésével: 
- cigarettafüst (saját vagy másé) 
- beltéri légszennyezettség, pl. por, tisztítószerek, hajlakk, erős szagú parfümök, 
légfrissítők, vagy illatosított gyertyák 
- foglalkozási légyszennyezettség, pl. szénpor, kemikáliák, füst, gőz 
- kültéri légszennyezettség, pl. szmog, füst, kipufogógáz 
- fertőzések, különösen a megfázás, arcüreggyulladás, mellkasi fertőzések, 
tüdőgyulladás, influenza 
- allergia, különösen a háziállatokra és a háziporra 
- szorongás, stressz 
- időváltozás, extrém hideg és meleg időszak, erős szél, magas páratartalom 
- a napi gyógyszeradag használatának elmulasztása 
Kezelés 
Számos különböző gyógyszer áll rendelkezésünkre a COPD kezelésében. A választás 
attól függ, hogy milyen tünetek vannak jelen, hogy mennyire súlyos a betegség, illetve 
hogy az egy adott állapot szinten tartására (fenntartó kezelés) vagy egy hirtelen 
bekövetkezett állapotromlás (exacerbáció) kezelésére adjuk. Néha az orvos – az aktuális 








Hosszú hatású hörgőtágítók – segítenek nyitva tartani a légutakat azáltal, hogy a 
légutakat körülvevő izmok összehúzódásának szabályozásával tágítják azokat. A 
hörgőtágítókat a beteg belélegezheti (ez a leghatékonyabb módszer), vagy tablettaként 
szájon át is beveheti. A fenntartó kezelésre használt hörgőtágítók rendszerint hosszú 
hatásúak (4-24 óra), éppen ezért fontos, hogy ezeket rendszeresen kell használni, a 
kontrollált állapot megtartása érdekében.  
Mukolitikumok (köptetők) – segítenek a váladék feloldásában, felszakadásában, ezáltal 
könnyebb felköhögni. A köptetők használatánál fontos a bő folyadékbevitel.  
Szteroidok – belégzéssel vagy tabletta formájában adagolhatóak. A szteroid csökkenti a 
légúti nyálkahártya duzzanatát és általában hörgőtágítóval kombinálva adják súlyos 
COPD-ben. Nagyon fontos a szteroid rendszeres használata, még akkor is, ha a beteg 
jól érzi magát. Amennyiben a beteg abba szeretné hagyni a szteroid használatát, 
feltétlenül beszélje meg a kezelőorvosával, mert a szteroid hirtelen felfüggesztése súlyos 
következményekkel járhat.  
Oxigén – általában csak azok a súlyos állapotú COPD-sek kapják, akiknek a vére 
nagyon kevés oxigént tartalmaz. Amennyiben szükséges, akkor az orvosa ellenőrzi a 
vér oxigéntartalmát, majd az oxigénkezelés megkezdése után megismétli a vizsgálatot, 
hogy meggyőződjön arról, hogy javított-e az állapotán.  
Védőoltások – fontosak annak érdekében, hogy elkerüljük azokat a fertőző 
betegségeket, amelyek a COPD tüneteinek súlyos romlásához, exacerbációhoz 
vezethetnek. Általában ajánlott a COPD-s betegek számára az influenza vakcina 
évenként beadása.  
Rövid hatású hörgőtárgítók – a gyors és rövid hatású inhalációs hörgőtágítókat 
rendszerint a COPD heveny fázisában adják a betegnek. A hatástartamuk 4-6 óra, a 
légzést könnyítik. Ha a tünetek súlyosak, akkor célszerűbb a hagyományos  túlnyomásos 







Teofillinek – ritkábban, általában tabletta formájában alkalmazzák a COPD-s tünetek 
enyhítésére. Lassan tágítják a légutakat, megkönnyítve ezáltal a légzést, és segíthetnek 
a légutak gyulladásának csökkentésében is. Mivel viszonylag gyakran okozhatnak 
mellékhatásokat, ezért szükséges a vér teofillin-szintjének rendszeres ellenőrzése. 
Rohamoldó terápia 
Szteroidok – gyakran adják rövid ideig a tünetek fellángolása esetén, a légúti 
nyálkahártya duzzanatának csökkentésére.  
Oxigén – az akut fellángolás időszakában oxigénmaszkon keresztül adható, ha a vér 
oxigénszintje alacsony.  
COPD-sként élni 
Az orvos által előírt gyógyszerek alkalmazása mellett nagyon sok dolog létezik, amit 
önállóan megtehetünk a tüneteink javítása érdekében, hogy a mindennapi életben jobban 
érezzük magunkat.  
Hagyja abba a dohányzást! 
A dohányzás a legrosszabb dolog, amit egy COPD-s tehet. A dohányzás abbahagyásával 
csökkenthetők a tünetek, lassítható a betegség progressziója és megelőzhetőek a 
fellángolások. Soha nem késő letenni a cigarettát. 
Kérje orvosa tanácsát a dohányzás abbahagyásával kapcsolatban. Néhány ember 
könnyedén le tudja tenni a cigarettát, ha megérti, hogy a dohányzás már mennyi kárt 
okozott neki. Másoknak (a többségnek) ez nehezebben megy és rosszul érzik magukat 
a leszokás kezdetén.  
Minden füstmentes nappal könnyebb lesz! 
Gondoljon arra, hogy miért dohányzik és azokra a pillanatokra, amikor úgy érzi, rá kell 
gyújtania – próbálja meg kitalálni, hogyan kezelheti ezeket a helyzeteket dohányzás 
nélkül! Néhány hasznos módszer másoknak is segített: 








- jutalmazási rendszer – jutalmazza meg saját magát, ha sikerült rágyújtás nélkül 
eltöltenie az előre kijelölt időt (nap, hét, hónap) 
- leszokás saját erőből – jelöljön ki egy napot, amikor abba szeretné hagyni a 
dohányzást, és hagyja is abba! 
- támogató csoport – azok az emberek, akik hasonló helyzetben vannak vagy 
voltak, segíthetnek a cigaretta letételében. Később Ön is segíthet majd 
másoknak… 
- Kerülje a dohányfüstöt – mások dohányzása is káros hatással lehet az Ön COPD-
s tüneteire, illetve arra, hogy meg tudja-e állni, hogy ne gyújtson rá! Kerülje a 
dohányzásra kijelölt helyeket, vagy kérje meg a dohányzókat, hogy kint 
dohányozzanak.  
A kiváltó okok kerülése 
Kerüljön minden olyan anyagot vagy helyzetet, amelyek előidézhetik a COPD-s 
tüneteinek romlását! Ilyenek a füst, az erős szagok, hajlakk, környezeti 
légszennyezettség és a stressz. Győződjön meg arról, hogy otthona jól szellőzik, és 
használjon párásítót, ha nagyon száraz a levegő! 
Légzéstechnikák 
A légzőgyakorlat a napi rutin része. Ha rendszeresen alkalmazza ezeket a gyakorlatokat, 
automatikussá válnak, így a későbbiekben képes lesz javítani a légzését a mindennapi 
tevékenységei vagy a szokásosnál megerőltetőbb feladatainak elvégzése közben. 
Különböző légzési technikákat ajánlanak a COPD-s betegek számára. A leginkább 
elfogadott technika az összehúzott ajakkal történő, úgynevezett ajakfékes légzés.  
Az ajakfékes légzés alapjai 
1. Tegye a kezét csípőre, majd lélegezzen be lassan és mélyen az orrán keresztül.  
2. Várjon egy vagy két másodpercet, majd húzza össze ajkait, mint amikor 
szívószálon keresztül iszik vagy fütyül! 
3. Fújja ki a levegőt szép lassan és teljesen összecsücsörített ajkain keresztül, de 
erőltesse, hogy az utolsó csepp levegőt is kifújja a tüdejéből! 







5. Néhány embernek akkor is segít ez a légzéstechnika, amikor fulladnak vagy 
stresszes állapotban vannak.  
Testtartás 
Ülő vagy álló testhelyzet is segítheti a maximális tüdőkapacitás (a legnagyobb 
belélegezhető levegőmennyiség) elérését. Ha görnyedten ül, vagy hajlottan áll, akkor a 
tüdő befogadóképessége csökken, és így nehezebben tudja teleszívni a tüdejét 
levegővel. Helyes testtartás mellett javul a közérzete és légzése is könnyebbé válik. 
Fulladás esetén bizonyos testtartásokat használva javíthat a légzésén. Válassza azt a 
pozíciót, amelyik az Ön számára a legkényelmesebb! 
Ülő testhelyzet 
Helyezze a lábait a földre (telitalppal), és tartsa a hatát a legegyenesebben, pihentesse 
az állát a kezein, vagy tegyen egy párnát az asztalra és fektesse rá karjait és fejét! 
Figyeljen a légzésére, és próbálja minél hosszabbra nyújtani a légézését! 
Álló testhelyzet 
Próbáljon kissé előrehajolni, kapaszkodjon az asztalba, vagy a szék háttámlájába! Ha 
nincs semmi, amiben kapaszkodni tudna, akkor helyezze a kezét a combjára és dőljön 
egy kicsit előre! Majd ugyanúgy, mint az ülő testhelyzetben, próbálja meg kontrollálni 
a légzését! 
Étrend 
- Gondoskodjon a bő folyadékbevitelről, lehetőleg koffein- és alkoholmentes 
italokat fogyasszon, amelyek segítenek feloldani a váladékot! 
- Az egészséges, kiegyensúlyozott étrend bővelkedik fehérjében (sovány húsok, 
halak), energiadús, így kevésbé érzi magát fáradtnak.  
- Próbáljon többször kis adagban étkezni, így elkerülhető a puffadásérzés, illetve 
az étkezéskor jelentkező fulladás! 
Testmozgás 








- Válassza  ki az Önnek legmegfelelőbb mozgásgyakorlatokat, amelyek elvégzése 
élvezetet nyújt. Nem csak a hangos edzőtermekben lehet nagy hatásfokú 
zsírégető gyakorlatokat végezni! 
- Tűzze ki célul, hogy minden nap tornázzon egy kicsit! 
- A légzésrehabilitáció vagy edzésprogram nagyon hasznos a legtöbb COPD-s 
beteg számára és a gyakorlatok otthon is kivitelezhetőek.  
- Próbálja úgy végezni a légzőgyakorlatokat, hogy ne fulladjon ki túlságosan! 
Pihenés 
- A relaxációs technikák segíthetnek megnyugtatni a légzést, tágítják a tüdőt és 
megelőzik a stressz által okozott tüneteket, illetve állapotromlásokat. 
- Ajakfékes légzéssel is könnyítheti a légzését.  
- Másik hasznos módszer, ha szemeit lecsukva elképzel egy pozitív, megnyugtató 
képet és közben fej-, nyak- és vállmozgásokat végez, amelyek csökkentik a 
feszültséget. Keressen egy csendes, nyugodt helyet, ahol leülhet és megpihenhet 
egy kicsit! 
Fertőzések megelőzése 
- Próbálja meg kerülni a megfázott embereket, vagy azokat, akik köhögnek! Sok 
fertőzést meg tud előzni azzal, ha rendszeresen kezet most szappannal és vízzel, 
vagy kézfertőtlenítő folyadékot tart magánál, ha elmegy otthonról! 
- Figyeljen arra, hogy rendszeresen megkapja a szükséges védőoltásokat! Ha nem 
biztos abban, hogy megkapta azokat, kérdezze meg kezelőorvosát! 
Maradjon pozitív 
Jó élni. Ne feledje: 
- Kérje és fogadja el orvosa segítségét a dohányzás elhagyásában, a védőoltások 
felvételében, előzze meg a fertőzéseket, ismerje föl és enyhítse a hirtelen 
fellángoló tüneteket! 
- Szedje gyógyszereit az előírtaknak megfelelően! 







- Éljen jól! – COPD-sként is aktív maradhat. Működjön együtt az orvosával, 
együtt sikerülhet! 
Gyakran feltett kérdések 
Mit tehetek, ha hirtelen fulladni kezdek? 
Próbálja meg alkalmazni az ajakfékes légzési technikát! Keresse meg az okát, mitől 
alakulhatott ki a hirtelen fulladás és próbálja megszüntetni azt! Például, ha testmozgást 
vagy más fizikai tevékenységet végez, akkor függessze fel azokat, amíg légzése 
helyreáll! Ha füstös helyen van, akkor hagyja el mielőbb! 
Mikor kell orvoshoz fordulnom? 
Ha Ön sokkal rosszabbul érzi magát a szokásosnál, felmerül a légúti fertőzés lehetősége. 
Ha megváltozott a légzése, esetleg erősödött a köhögése, akkor mielőbb keresse fel az 
orvosát! 
Mikor kell kórházba mennem? 
Ha légzése hirtelen rosszabbodik, vagy ha úgy érzi, nem kap elég levegőt, akkor sürgős 
kórházi kezelésre van szüksége. Fontos, hogy legyen valaki, aki elviszi Önt a kórházba 
vagy értesíti a mentőt. Ön próbálja meg megőrizni a nyugalmát, amennyire csak lehet. 
Ha pánikba esik, az csak tovább súlyosbítja a tüneteit.  
Elmehetek nyaralni? 
A nyaralás egy nagyszerű alkalom a kikapcsolódásra. Beszélje meg orvosával és 
ellenőrizze, hogy van-e elegendő gyógyszere a hazaérkezésig. Ha messzebbre utazik, 
kérdezzen rá, hogy kell-e másik védőoltást kapnia előtte! Ha Ön repülőgépen fog utazni, 
és oxigénre van szüksége, akkor ezt foglaláskor jelezze a légitársaság felé, és ellenőrizze 
a magával vitt oxigénpalackra vonatkozó előírásokat! Ne feledje repülés során magánál 
tartani a gyógyszereit, még ha csak rövid ideig utazik is, mert a poggyászok 
elveszhetnek! Gondoskodjon arról, hogy távolléte alatt egészségbiztosítása fedezze az 
esetleges orvosi ellátás költségeit, ha a tünetek fellángolása miatt rászorulna.  







Csak azért, mert Ön beteg, nem kell feladni az élet örömeit. Ön nyugodtan folytathatja 
az eddigi szexuális életét, de bizonyos dolgokhoz alkalmazkodnia kell. Például 
használjon más testhelyzeteket, diszkréten végezzen légzésgyakorlatokat a szexuális 
aktus előtt vagy közben, megelőzvén ezzel a fulladást, tapasztalja ki a lehetőségeket, 
melyekkel energiáját, erőnlétét leginkább meg tudja őrizni! A legfontosabb, hogy 
beszélje meg partnerével, mennyiben korlátozza Önt a betegsége és ez milyen hatással 
lehet a viszonyukra! 
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